,

HELICOBACTER – Pylori Destroyer

(12 customer reviews)

$275.00

& Free Shipping
SKU: N/A Categories: ,
Guaranteed Safe Checkout

DISCOUNTS AND INCENTIVES :

  • Free $50 Interstellar Mug On Orders Over $500 (Choose Color At Checkout)
  • Free $95 Value Rush Worldwide Shipping On All Orders $750 Or More
  • Free $333 Value 75mm (3") Sterling Silver Interstellar Statement Pendant With $1500 Or More In Cart
  • 35% Off With $1000 Or More In Cart - Use Code "1000" (Excludes Combos)
  • 40% Off With $2000 Or More In Cart - Use Code "2000" (Excludes Combos)
  • 45% Off With $3000 Or More In Cart - Use Code "3000" (Excludes Combos)
  • 50% Off With $4000 Or More In Cart - Use Code "4000" (Excludes Combos)
  • 55% Off With $5000 Or More In Cart - Use Code "5000" (Excludes Combos)
  • 60% Off With $7500 Or More In Cart - Use Code "7500" (Excludes Combos)

100g bag

200:1 Concentration

1 out of 2 people has IT

Heartburn? Indigestion? Irritable bowel syndrome? Gas? Nutrient absorption issues? Ulcers? Stomach problems in general? There’s a high probability you have this resistant little bacteria camping out in your stomach wreaking havoc.

Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, helically-shaped, microaerophilic bacterium usually found in the stomach.[6] Its helical shape (from which the genus name, helicobacter, derives) is thought to have evolved in order to penetrate the mucoid lining of the stomach and thereby establish infection.[7][8] The bacterium was first identified in 1982 by Australian doctors Barry Marshall and Robin Warren, who found that it was present in a person with chronic gastritis and gastric ulcers, conditions not previously believed to have a microbial cause.[9][10][11] H. pylori has also been linked to the development of duodenal ulcerspolyps, i. e. benign growths, in the small intestine, large intestine, and rectum, and malignancies of the stomach’s secretory glands (termed stomach adenocarcinoma),[12] of the mucosa-associated lymphoid tissue in the stomach, esophagus, colon, rectum, or tissues around the eye (termed extranodal marginal zone B-cell lymphoma of the cited organ),[13][14][15] and of lymphoid tissue in the stomach (termed diffuse large B-cell lymphoma).[16]

Many investigators have proposed causal associations between H. pylori and a wide range of other diseases (e.g. idiopathic thrombocytopenic purpurairon deficiency anemiaatherosclerosisAlzheimer’s disease,[17] multiple sclerosiscoronary artery diseaseperiodontitis,[18] Parkinson’s diseaseGuillain–Barré syndromerosaceapsoriasischronic urticariaspot baldness, various autoimmune skin diseasesHenoch–Schönlein purpura, low blood levels of vitamin B12autoimmune neutropenia, the antiphospholipid syndromeplasma cell dyscrasiascentral serous chorioretinitisopen angle glaucomablepharitisdiabetes mellitus, the metabolic syndrome, various types of allergiesnon-alcoholic fatty liver disease, non-alcoholic steatohepatitishepatic fibrosis, and liver cancer[19]). The bacterial infection has also been proposed to have protective effects for its hosts against infections by other pathogensasthma, obesity,[17] celiac diseaseinflammatory bowel disease,[18] rhinitisatopic dermatitis,[20] gastroesophageal reflux disease,[21] and esophageal cancer.[21] However, these deleterious and protective effects have frequently been based on correlative rather than direct relationship studies[18] and have often been contradicted by other studies that show either the opposite or no effect on the cited disease.[19] Consequently, many of these relationships are currently regarded as questionable and in need of more definitive studes.[17] They are not considered further here.

Some studies suggest that H. pylori plays an important role in the natural stomach ecology, e.g. by influencing the type of bacteria that colonize the gastrointestinal tract.[22][19] Other studies suggest that non-pathogenic strains of H. pylori may be beneficial, e.g., by normalizing stomach acid secretion,[23] and may play a role in regulating appetite, since the bacterium’s presence in the stomach results in a persistent but reversible reduction in the level of ghrelin, an hormone that increases appetite.[23]

In general, over 50% of the world’s population has H. pylori in their upper gastrointestinal tracts[5] with this infection (or colonization) being more common in developing countries.[4] In recent decades, however the prevalence of H. pylori colonization of the gastrointestinal tract has declined in many countries. This is attributed to improved socioeconomic conditions: in the United States of America, for example, the prevalence of H. pylori, as detected by endoscopy conducted on a referral population, fell from 65.8 to 6.8% over a recent 10 year period while over the same time period in some developing countries H. pylori colonization remained very common with prevalence levels as high as 80%.[24] In all events, H. pylori infection is usually asymptomatic, being associated with overt disease (commonly gastritis or peptic ulcers rather than the relatively very rarely occurring cancers) in less than 20% of cases.[25].” – WIKI

 


Inflammation, DNA Damage, Helicobacter pyloriand Gastric Tumorigenesis


Helicobacter pylori (H. pylori) is a Gram negative bacterium that colonizes the stomach of almost half human population. It has evolved to escape immune surveillance, establishes lifelong inflammation, predisposing to genomic instability and DNA damage, notably double strand breaks. The epithelial host cell responds by activation of DNA damage repair (DDR) machinery that seems to be compromised by the infection. It is therefore now accepted that genetic damage is a major mechanism operating in cases of H. pylori induced carcinogenesis. Here, we review the data on the molecular pathways involved in DNA damage and DDR activation during H. pylori infection.


Helicobacter pylori-induced premature senescence


Helicobacter pylori, one of the most frequently observed bacterium in the human intestinal flora, has been widely studied since Marshall and Warren documented a link between the presence of H. pylori in the gastrointestinal tract and gastritis and gastric ulcers. Interestingly, H. pylori has also been found in several other epithelial tissues, including the eyes, ears, nose and skin that may have direct or indirect effects on host physiology and may contribute to extragastric diseases, e.g. chronic skin diseases. More recently, it has been shown that H. pylori cytotoxin CagA expression induces cellular senescenceof human gastric nonpolarized epithelial cells that may lead to gastrointestinal disorders and systemic inflammation. Here, we hypothesize that also chronic skin diseases may be promoted by stress-induced premature senescence (SIPS) of skin cells, namely fibroblasts and keratinocytes, stimulated with H. pylori cytotoxins. Future studies involving cell culture models and clinical specimens are needed to verify the involvement of H. pylori in SIPS-based chronic skin diseases.


H. pylori infection leads to an increased rate of diabetes


CONCLUSIONS We demonstrated for the first time that H. pylori infection leads to an increased rate of incident diabetes in a prospective cohort study. Our findings implicate a potential role for antibiotic and gastrointestinal treatment in preventing diabetes.


Proton Pump Inhibitors Accelerate Endothelial Senescence


Rationale: Proton pump inhibitors (PPIs) are popular drugs for gastroesophageal reflux, which are now available for long-term use without medical supervision. Recent reports suggest that PPI use is associated with cardiovascular, renal, and neurological morbidity.

Objective: To study the long-term effect of PPIs on endothelial dysfunction and senescence and investigate the mechanism involved in PPI-induced vascular dysfunction.

Methods and Results: Chronic exposure to PPIs impaired endothelial function and accelerated human endothelial senescence by reducing telomere length.

Conclusions:Our data may provide a unifying mechanism for the association of PPI use with increased risk of cardiovascular, renal, and neurological morbidity and mortality.

A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2α: a potential role for targeting HIF-2α to prevent and treat reflux esophagitis.


Traditionally, reflux esophagitis was assumed to develop as a caustic, chemical injury inflicted by refluxed acid. Recently, however, studies in rats and humans suggest that reflux esophagitis develops as a cytokine-mediated inflammatory injury, with hypoxia inducible factor (HIF)-2α playing a major role. In response to the reflux of acid and bile, HIF-2α in esophageal epithelial cells becomes stabilized, thereby increasing production of pro-inflammatory cytokines that attract T lymphocytes and other inflammatory cells to damage the esophagus. Recent studies have identified small molecule inhibitors of HIF-2α that demonstrate exquisite isoform selectivity, and clinical trials for treatment of HIF-2α-driven kidney cancers are ongoing. It is conceivable that a HIF-2α-directed therapy might be a novel approach to prevention and treatment of reflux esophagitis.


The Helicobacter pylori Urease Virulence Factor Is Required for the Induction of Hypoxia-Induced Factor-1α in Gastric Cells


Chronic Helicobacter pylori infection increases the risk of gastric cancer and induction of hypoxia-induced factor (HIF), which is frequently associated with the development and progression of several types of cancer. We recently showed that H. pylori activation of the PI3K-AKT-mTOR pathway in gastric cells increased HIF-1α expression. Here, we identified the H. pylori virulence factor responsible for HIF-1α induction. A mutant of the H. pylori 84-183 strain was identified with reduced ability to induce HIF-1α. Coomassie blue staining of extracts from these bacteria separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) revealed poor expression of urease subunits that correlated with reduced urease activity. This finding was confirmed in the 26695 strain, where urease mutants were unable to induce HIF-1α expression. Of note, HIF-1α induction was also observed in the presence of the urease inhibitor acetohydroxamic acid at concentrations (of 20 mM) that abrogated urease activity in bacterial culture supernatants, suggesting that enzymatic activity of the urease is not required for HIF-1α induction. Finally, the pre-incubation of the human gastric adenocarcinoma cell line AGS with blocking antibodies against Toll-like receptor-2 (TLR2), but not TLR4, prevented HIF-1α induction. In summary, these results reveal a hitherto unexpected role for the urease protein in HIF-1α induction via TLR2 activation following H. pylori infection of gastric cells.

INGREDIENTS:

Abrus cantoniensis (Fabaceae)
Agaricus bisporus extract

Ageratum conyzoides extract


Allicin

Bifidobacterium bifidum

Bombax malabaricum DC. Extract

Broccoli sprouts (sulforaphane)

Capsaicin

Carthamus tinctorious  extract

Cassia twig extract 

Celery Seed (novel unnamed component)

Coptis chinensis extract

Cranberry (Vaccinium macrocarpon)

Dateplum persimmon extrat

Decursin

EGCG

Eugenia caryophyllata (CLOVES)


Fructus amomi extract 

Golden cypress Cortex Phellodendri Chinensis) extract

Juglans regia extract

Korean Red Ginseng extract

L. rhamnosus GG

Lactobacillus reuteri

Lions Mane Mushroom

Luteolin

Lycopodium cernua

Mangnolia officinalis extract

Mastic Gum extract
Oregano

Plumbago zeylanica L. extract

Polygonum cuspidatum extract

  • Anti-Helicobacter pylori compounds from Polygonum cuspidatum

    Anti-Helicobacter pylori activity guided fractionation led to the isolation of five anthraquinones, two stilbenes and one naphthoquinone from the EtOAc fraction of Polygonum cuspidatum, using silica gel column chromatography, Sephadex-LH20, MPLC and recrystallization. The chemical structures were identified to be physcion (1), emodin (2), anthraglycoside B (3), trans-resveratrol (4), anthraglycoside A (5), polydatin (6), 2-methoxy-6-acetyl-7-methyljuglone (7) and citreorosein (8) by UV, 1H-NMR, 13C-NMR and mass spectrometry. Anti-Helicobacter pylori activity including MIC values of each compound was evaluated. All of the isolates exhibited anti-H. pylori activity of which MIC values were lower than that of a positive control, quercetin. Compounds 2 and 7 showed potent growth inhibitory activity. Especially, a naphthoquinone, compound 7 displayed most potent antibacterial activity with MIC50 value of 0.30 µM and MIC90 value of 0.39 µM. Although antiH. pylori activity of this plant was previously reported, this is the first report on that of compounds isolated from this species. From these findings, P. cuspidatum roots or its isolates may be useful for H. pylori infection and further study is needed to elucidate mechanism of action.


Punica granatum peel extract
Resveratrol

Rheum officinale extract

Rhizoma coptidis extract

Rottlerin (Mallotus philippinensis Muell. Arg (Euphorbiaceae)

Saccharomyces boulardii

Saussurea lappa (Asteraceae) Costus Root extract
Smilax glabra rhizome extract

Smoked plum (Fructus Pruni Mume) fruit extract

Tabebuia impetiginosa Martius ex DC dried inner bark (Menadione and plumbagin)

  • Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori.

    The growth-inhibiting activity of Tabebuia impetiginosa Martius ex DC dried inner bark-derived constituents against Helicobacter pylori ATCC 43504 was examined using paper disc diffusion and minimum inhibitory concentration (MIC) bioassays. The activity of the isolated compounds was compared to that of the commercially available anti-Helicobacter pylori agents, amoxicillin, metronidazole, and tetracycline. The biologically active components of Tabebuia impetiginosa dried inner bark (taheebo) were characterized by spectroscopic analysis as 2-(hydroxymethyl)anthraquinone, anthraquinone-2-carboxylic acid, and 2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone (lapachol). With the paper disc diffusion assay 2-(hydroxymethyl)anthraquinone exhibited strong activity against Helicobacter pylori ATCC 43504 at 0.01 mg/disc. Anthraquinone-2-carboxylic acid, lapachol and metronidazole were less effective, exhibiting moderate anti-Helicobacter pylori activity at 0.1 mg/disc. Amoxicillin and tetracycline were the most potent compounds tested, displaying very strong activity at 0.005 mg/disc. 2-(Hydroxymethyl)anthraquinone exhibited moderate activity at this dose. Tetracycline still had strong activity at 0.001 mg/disc while amoxicillin had little activity at this dose. In the MIC bioassay, 2-(hydroxymethyl)anthraquinone (2 microg/mL), anthraquinone-2-carboxylic acid (8 microg/mL), and lapachol (4 microg/mL) were more active than metronidazole (32 microg/mL) but less effective than amoxicillin (0.063 microg/mL) and tetracycline (0.5 microg/mL).

  • The anti-Helicobacter pylori activity of seven 1,4-naphthoquinone derivatives (structurally related to lapachol), 1,4-naphthoquinone, 5,8-dihydroxy-1,4-naphthoquinone (naphthazarin), 2-methyl-1,4-naphthoquinone (menadione), 2-hydroxy-1,4-naphthoquinone (lawsone), 5-hydroxy-2-methyl-1,4-naphthoquinone (plumbagin), 5-hydroxy-1,4-naphthoquinone (juglone), and 2,3-dichloro-1,4-naphthoquinone (dichlone) was also evaluated using the paper disc assay. Menadione and plumbagin were the most potent compounds tested with the later still exhibiting very strong activity at 0.001 mg/disc. Menadione, juglone and tetracycline had strong activity at this low dose while the latter two compounds and amoxicillin had very strong activity at 0.005 mg/disc.
  • Lawsone was unusual in that it had very strong activity at 0.1 and 0.05 mg/disc but weak activity at doses of 0.01 mg/disc and lower. Naphthazalin, lapachol and dichlone had similar activities while metronidazole had the lowest activity of all compounds tested. These results may be an indication of at least one of the pharmacological actions of taheebo. The Tabebuia impetiginosa dried inner bark-derived materials, particularly 2-(hydroxymethyl)anthraquinone, merit further study as potential Helicobacter pylori eradicating agents or lead compounds.

tyrosol-elenolic acid dialdehyde (Ty-EDA or Ty-DEA) from Olive oil

  • In vitro activity of olive oil polyphenols against Helicobacter pylori.

    Helicobacter pylori is linked to a majority of peptic ulcers and to some types of gastric cancer, and resistance of the microorganism to antibiotic treatment is now found worldwide. Virgin olive oil is an unrefined vegetable oil that contains a significant amount of phenolic compounds. Under simulated conditions, we have demonstrated that these substances can diffuse from the oil into the gastric juice and be stable for hours in this acidic environment. In vitro, they exerted a strong bactericidal activity against eight strains of H. pylori, three of them resistant to some antibiotics. Among the phenolic compounds, the dialdehydic form of decarboxymethyl ligstroside aglycon showed the strongest bactericidal effect at a concentration as low as 1.3 microg/mL.

  • Although the experimental conditions are different from other reported works, this bactericidal concentration is much lower than those found for phenolic compounds from tea, wine, and plant extracts. These results open the possibility of considering virgin olive oil a chemopreventive agent for peptic ulcer or gastric cancer, but this bioactivity should be confirmed in vivo in the future.

Wasabi (Wasabia japonica) extract

Zinc Carnosine
  • A modified sequential regimen of Helicobacter pylori treatment enforced by Bacillus clausii and Zinc Carnosine complex yields high eradication rates

    Introduction: Over the past decade a worldwide trend of decline in the cure rates of Helicobacter pylori is observed. Current eradication rates achieved by the standard triple therapy are below 70%. Sequential therapy had provided a potential alternative that would compensate for the unmet performance of triple therapy. Despite its superiority to triple therapy, the excellent results reported initially were not reproduced by other investigators work. Adding adjuvant agents was also found to improve further the success rate of eradication. Probiotics emerged as a useful adjunct in treatment and prophylaxis of Helicobacter pylori infection. The nutritional supplement Zinc carnosine complex is another adjuvant which is believed to add value to the treatment. Patients and method: an open label randomized observational clinical study designed to compare the efficacy of a modified sequential regimen enforced by two adjuvants the probiotic Bacillus clausii and the nutritional Zinc Carnosine supplement. Patients who fulfilled the inclusion and exclusion criteria were randomized to one of two groups who were given the same components of the regimen of treatment either with clarithromycin (group A, n=131) or levofloxacin replacing it (group B, n=137) and were compared against the current reported response to triple therapy in our area (67.9%). Results: This regimen of eradication had yielded a Per protocol cure rate of 96.4% and an ITT rate of 89.9% for the levofloxacin based therapy. The Per protocol eradication rate for the clarithromycin based treatments was 93.4% and the ITT rate was 90%. The response was not significantly affected by previous exposure to the antibiotics used. Patient satisfaction and compliance were remarkable with most patients having a significant feeling of wellbeing and improvement of their symptoms. Side effects to the components of the regimen were unremarkable. The addition of Bacillus clausii and the nutritional supplement Zinc Carnosine had added great value to the eradication response.


Scientific Studies:
  1. Helicobacter pylori Infection
  2. Helicobacter pylori and gastric carcinogenesis.
  3. Schistosomes, liver flukes and Helicobacter pylori.
  4. Helicobacter pylori Infection and Gastric Lymphoma
  5. Helicobacter pylori and gastrointestinal tract adenocarcinomas
  6. The prevalence of Helicobacter pylori infection in different countries.
  7. Helicobacter pylori Infection and the Development of Gastric Cancer
  8. Helicobacter pylori Infection and the Risk of Gastric Carcinoma
  9. Pathogenesis of Helicobacter pylori Infection
  10. Helicobacter pylori Virulence and Genetic Geography
  11. The epidemiology of Helicobacter pylori infection.
  12. The incidence of Helicobacter pylori infection.
  13. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma
  14. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori
  15. Isolation of Helicobacter pylori from human faeces
  16. The Cohort Effect and Helicobacter pylori
  17. Helicobacter pylori and Peptic Ulcer Disease
  18. Helicobacter pylori persistence: biology and disease
  19. Carcinogenesis of Helicobacter pylori
  20. Long-term sequelae of Helicobacter pylori gastritis
  21. Free recombination within Helicobacter pylori
  22. The complete genome sequence of the gastric pathogen Helicobacter pylori
  23. Traces of Human Migrations in Helicobacter pylori Populations
  24. Epidemiology of Helicobacter pylori infection.
  25. The protein–protein interaction map of Helicobacter pylori
  26. Relation of Helicobacter pylori infection and coronary heart disease.
  27. Helicobacter pylori: the African enigma.
  28. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils
  29. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
  30. The prevalence of Helicobacter pylori in peptic ulcer disease.
  31. Helicobacter pylori: Epidemiology and Routes of Transmission
  32. Helicobacter pylori Infection and Gastric Carcinoma among Japanese Americans in Hawaii
  33. Intrafamilial Clustering of Helicobacter pylori Infection
  34. Cure of duodenal ulcer associated with eradication of Helicobacter pylori
  35. Helicobacter pylori and gastric diseases
  36. An international association between Helicobacter pylori infection and gastric cancer
  37. Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report
  38. Helicobacter pylori: gastric cancer and beyond
  39. Epidemiology of Helicobacter pylori Infection
  40. Helicobacter pylori in Health and Disease
  41. Helicobacter pylori and the Pathogenesis of Gastroduodenal Inflammation
  42. Helicobacter pylori and gastric cancer.
  43. Epidemiology of Helicobacter pylori Infection
  44. Helicobacter pylori Infection in Children: A Consensus Statement
  45. Epidemiology of Helicobacter pylori infection
  46. Helicobacter pylori Vacuolating Cytotoxin Inhibits T Lymphocyte Activation
  47. Helicobacter pylorir Current Status
  48. Eradication of Helicobacter pylori for non‐ulcer dyspepsia
  49. Helicobacter pylori infection and chronic gastric acid hyposecretion
  50. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
  51. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation
  52. The primary transcriptome of the major human pathogen Helicobacter pylori
  53. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report
  54. Childhood living conditions and Helicobacter pylori seropositivity in adult life
  55. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., Respectively
  56. Helicobacter pylori and Atrophic Gastritis: Importance of the cagA Status
  57. Development of Helicobacter pylori-induced Gastric Carcinoma in Mongolian Gerbils
  58. Helicobacter pylori treatment in the era of increasing antibiotic resistance
  59. Host-Bacterial Interactions in Helicobacter pylori Infection
  60. Gastric Adenocarcinoma and Helicobacter pylori Infection
  61. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains.
  62. Helicobacter pylori Adhesin Binding Fucosylated Histo-Blood Group Antigens Revealed by Retagging
  63. Helicobacter pylori SabA Adhesin in Persistent Infection and Chronic Inflammation
  64. Translocation of Helicobacter pylori CagA into Gastric Epithelial Cells by Type IV Secretion
  65. Factors influencing the eradication of Helicobacter pylori with triple therapy
  66. Disruption of the Epithelial Apical-Junctional Complex by Helicobacter pylori CagA
  67. The vacuolating cytotoxin of Helicobacter pylori
  68. Microbiology of Helicobacter pylori.
  69. Seroconversion for Helicobacter pylori
  70. SHP-2 Tyrosine Phosphatase as an Intracellular Target of Helicobacter pylori CagA Protein
  71. Isolation of Helicobacter pylori from saliva.
  72. Mechanisms of disease: Helicobacter pylori virulence factors
  73. Helicobacter pylori infection
  74. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island
  75. An African origin for the intimate association between humans and Helicobacter pylori
  76. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens
  77. Helicobacter pylori in Peptic Ulcer Disease
  78. Epidemiology of Helicobacter pylori Infection and Public Health Implications
  79. Kyoto global consensus report on Helicobacter pylori gastritis
  80. Helicobacter pylori and antibiotic resistance
  81. Pathogenicity of Helicobacter pylori: a perspective.
  82. Analyses of the cag pathogenicity island of Helicobacter pylori
  83. Transmission of Helicobacter pylori among siblings
  84. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer
  85. Helicobacter pylori Detection and Antimicrobial Susceptibility Testing
  86. Anti-Helicobacter pylori flavonoids from licorice extract
  87. Helicobacter pylori and Probiotics
  88. Purification and characterization of the vacuolating toxin from Helicobacter pylori.
  89. A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain
  90. Natural history and epidemiology of Helicobacter pylori infection
  91. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection
  92. Helicobacter pylori in the drinking water in Peru
  93. Antibiotic resistance in Helicobacter pylori: Implications for therapy
  94. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors
  95. Helicobacter pylori: Its Role in Disease
  96. Helicobacter pylori VacA, a paradigm for toxin multifunctionality
  97. Geographic distribution of vacA allelic types of Helicobacter pylori
  98. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis
  99. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
  100. Activation of β-catenin by carcinogenic Helicobacter pylori
  101. Complex polysaccharides as PCR inhibitors in feces: Helicobacter pylori model.
  102. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains
  103. Determinants of Helicobacter pylori pathogenicity.
  104. Expanding Allelic Diversity of Helicobacter pylori vacA
  105. Water source as risk factor for Helicobacter pylori infection in Peruvian children
  106. Prevalence of Helicobacter pylori Infection and Histologic Gastritis in Asymptomatic Persons
  107. Helicobacter pylori Infection: Genetic and Environmental Influences: A Study of Twins
  108. Ecology of Helicobacter pylori in the Human Stomach
  109. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.
  110. Treatment of Helicobacter pylori infection
  111. Mastic Gum Kills Helicobacter pylori
  112. Eradication Therapy for Helicobacter pylori
  113. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation.
  114. European Multicentre Survey of in Vitro Antimicrobial Resistance in Helicobacter pylori
  115. Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk
  116. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection
  117. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori
  118. Effect of Treatment of Helicobacter pylori Infection on the Long-term Recurrence of Gastric or Duodenal Ulcer: A Randomized, Controlled Study
  119. Genome-Scale Metabolic Model of Helicobacter pylori 26695
  120. Second Asia–Pacific Consensus Guidelines for Helicobacter pylori infection
  121. DNA diversity among clinical isolates of Helicobacter pylori detected by PCR-based RAPD fingerprinting
  122. Helicobacter pylori and Gastric Cancer
  123. Helicobacter pylori and gastric inflammation
  124. RECENT DEVELOPMENTS IN THE EPIDEMIOLOGY OF Helicobacter pylori
  125. Symptomatic Benefit from Eradicating Helicobacter pylori Infection in Patients with Nonulcer Dyspepsia
  126. Characterization of a Helicobacter pylori neutrophil-activating protein.
  127. Helicobacter pylori and gastric adenocarcinoma
  128. Serologic detection of infection with cagA+ Helicobacter pylori strains.
  129. Sequential Therapy versus Standard Triple-Drug Therapy forHelicobacter pyloriEradication
  130. A Report Card to Grade Helicobacter pylori Therapy
  131. When is Helicobacter pylori infection acquired?
  132. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology
  133. Living dangerously: how Helicobacter pylori survives in the human stomach
  134. Helicobacter pylori genetic diversity and risk of human disease
  135. Local Cytokine Response in Helicobacter pylori-Infected Subjects
  136. Helicobacter pylori infection and duodenal ulcer disease.
  137. Comparative proteome analysis of Helicobacter pylori
  138. Screening dyspepsia by serology to Helicobacter pylori
  139. Helicobacter pylori, Gastroduodenal Disease, and Recurrent Abdominal Pain in Children
  140. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption
  141. THE PATHOGENESIS OF Helicobacter pylori–INDUCED GASTRO-DUODENAL DISEASES
  142. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura
  143. Changes in the gastric mucosa following eradication of Helicobacter pylori.
  144. Helicobacter pylori and gastric carcinogenesis
  145. Helicobacter pylori and Gastroduodenal Disease
  146. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population
  147. Seroprevalence of Helicobacter pylori Infections in Thailand
  148. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up
  149. Transmission of Helicobacter pylori: faecal-oral versus oral-oral route.
  150. Resistance of Helicobacter pylori to antibiotics
  151. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection
  152. Diagnosis of Helicobacter pylori infection.
  153. Plasma ghrelin following cure of Helicobacter pylori
  154. Purification and characterization of urease from Helicobacter pylori.
  155. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin
  156. Supramolecular assembly and acid resistance of Helicobacter pylori urease
  157. Age-Specific Incidence of Helicobacter pylori
  158. Helicobacter pylori Infection and Dyspepsia
  159. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer
  160. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies.
  161. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
  162. Epithelial attachment alters the outcome of Helicobacter pylori infection
  163. Mechanisms involved in Helicobacter pylori—Induced inflammation
  164. Development of a mouse model of Helicobacter pylori infection that mimics human disease
  165. Helicobacter pylori Infection and the Risk for Duodenal and Gastric Ulceration
  166. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo.
  167. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts
  168. Inverse Associations of Helicobacter pylori With Asthma and Allergy
  169. Helicobacter pylori Caga Protein Can Be Tyrosine Phosphorylated in Gastric Epithelial Cells
  170. A Mr 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori
  171. Amoxicillin and omeprazole to eradicate Helicobacter pylori
  172. Molecular Hydrogen as an Energy Source for Helicobacter pylori
  173. Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation
  174. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review
  175. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications
  176. Infection with Helicobacter pylori Strains Possessing cagA Is Associated with an Increased Risk of Developing Adenocarcinoma of the Stomach
  177. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes.
  178. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori
  179. Diagnosing Helicobacter pylori In Vivo by Confocal Laser Endoscopy
  180. The coccoid forms of Helicobacter pylori. Criteria for their viability
  181. Increased Oxidative DNA Damage in Helicobacter pylori-infected Human Gastric Mucosa
  182. Chemoprevention of Gastric Dysplasia: Randomized Trial of Antioxidant Supplements and Anti-Helicobacter pylori Therapy
  183. Helicobacter pylori Infection Has No Role in the Pathogenesis of Reflux Esophagitis
  184. Sensitive detection of Helicobacter pylori by using polymerase chain reaction.
  185. Helicobacter pylori-Negative Duodenal Ulcer.
  186. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection.
  187. Helicobacter pylori catalase
  188. Inhibition of Helicobacter pylori by garlic extract ( Allium sativum)
  189. Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of ChinaA Randomized Controlled Trial
  190. Association of Virulent Helicobacter pylori Strains With Ischemic Heart Disease
  191. The urea breath test for Helicobacter pylori.
  192. Helicobacter pylori infection: Independent risk indicator of gastric adenocarcinoma
  193. Lack of Effect of Treating Helicobacter pylori Infection in Patients with Nonulcer Dyspepsia
  194. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets.
  195. Helicobacter pylori in the pediatric patient.
  196. Clinical Relevance of Helicobacter pylori cagA and vacA Gene Polymorphisms
  197. Antibacterial Treatment of Gastric Ulcers Associated with Helicobacter pylori
  198. Diagnosis of Helicobacter pylori infection with a new non-in vasive antigen-based assay
  199. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors
  200. Duodenal ulcer promoting gene of Helicobacter pylori
  201. Helicobacter pylori Infection in Intestinal- and Diffuse-Type Gastric Adenocarcinomas
  202. Treatment of Helicobacter pylori Infection: A Review of the World Literature
  203. Helicobacter pylori gastritis and primary gastric non-Hodgkin’s lymphomas.
  204. Eradication of Helicobacter pylori with clarithromycin and omeprazole.
  205. Fecal and Oral Shedding of Helicobacter pylori From Healthy Infected Adults
  206. Helicobacter pylori Colonization Is Inversely Associated with Childhood Asthma
  207. Helicobacter pylori infection causes antral gastritis
  208. Helicobacter pylori infection and chronic gastritis in gastric cancer.
  209. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells
  210. Atrophic Gastritis and Helicobacter pylori Infection in Patients with Reflux Esophagitis Treated with Omeprazole or Fundoplication
  211. Optimal therapy for Helicobacter pylori infections
  212. Helicobacter pylori-induced gastric inflammation and gastric cancer
  213. Transmission and Epidemiology of Helicobacter pylori
  214. The clinical relevance of strain types of Helicobacter pylori.
  215. Gastric mucosal inflammatory responses to Helicobacter pylori.
  216. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains.
  217. Long term follow up of patients treated for Helicobacter pylori infection
  218. Clarithromycin-Resistant Genotypes and Eradication ofHelicobacter pylori
  219. Factors Influencing the Epidemiology of Helicobacter pylori Infection in Children
  220. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.
  221. Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori
  222. A H+-Gated Urea Channel: The Link Between Helicobacter pylori Urease and Gastric Colonization
  223. Establishment of gastric Helicobacter pylori infection in Mongolian gerbils.
  224. Helicobacter pylori: microbiology of a ‘slow’ bacterial infection
  225. Meta-Analysis of the Efficacy of Antibiotic Therapy in Eradicating Helicobacter pylori.
  226. Helicobacter pylori and gastric carcinoma
  227. The Treatment of Helicobacter pylori Infection in the Management of Peptic Ulcer Disease
  228. Epidemiological Features of Helicobacter pylori Infection in Developing Countries
  229. Mosaicism in Vacuolating Cytotoxin Alleles of Helicobacter pylori
    ASSOCIATION OF SPECIFIC vacA TYPES WITH CYTOTOXIN PRODUCTION AND PEPTIC ULCERATION
  230. A small animal model of human Helicobacter pylori active chronic gastritis
  231. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse
  232. Restriction and Modification Systems.
  233. Low biological activity of Helicobacter pylori lipopolysaccharide.
  234. Seroprevalence of Helicobacter pylori in South Korea
  235. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori
  236. Helicobacter pylori in Developing Countries. World Gastroenterology Organisation Global Guideline
  237. Helicobacter pylori infection in early gastric cancer development
  238. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori
  239. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: Effect of age, race, and socioeconomic status
  240. Epidemiology of Helicobacter pylori Infection
  241. The Complete Genome Sequence of Helicobacter pylori Strain G27
  242. Helicobacter pylori Infection in Children: Recommendations for Diagnosis and Treatment
  243. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis.
  244. Treatment of Peptic Ulcers Caused by Helicobacter pylori
  245. Pathophysiology of Helicobacter pylori Infection
  246. How is Helicobacter pylori Transmitted?
  247. Helicobacter pylori Genotypes May Determine Gastric Histopathology
  248. Hyperemesis Gravidarum Associated With Helicobacter pylori Seropositivity
  249. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity
  250. Helicobacter pylori in Human Carotid Atherosclerotic Plaques
  251. Oral immunization against Helicobacter pylori.
  252. Anti-Helicobacter pylori Activity of Hearbal Medicines
  253. Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management.
  254. Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue
  255. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa.
  256. Helicobacter pylori increases proliferation of gastric epithelial cells.
  257. Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey.
  258. Antibacterial activity of black myrobalan (Terminalia chebula Retz) against Helicobacter pylori
  259. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease.
  260. Screening of Turkish anti-ulcerogenic folk remedies for anti-Helicobacter pylori activity
  261. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease
  262. Immune and Inflammatory Responses to Helicobacter pylori Infection
  263. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori
  264. Helicobacter pylori and gastric carcinoma: Serum antibody prevalence in populations with contrasting cancer risks
  265. Stable amoxicillin resistance in Helicobacter pylori
  266. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
  267. New concepts of resistance in the treatment of Helicobacter pylori infections
  268. Role of type IV secretion in Helicobacter pylori pathogenesis
  269. Helicobacter pylori outer membrane proteins and gastroduodenal disease
  270. Recombination and clonal groupings within Helicobacter pylori from different geographical regions
  271. Cure of duodenal ulcer after eradication of Helicobacter pylori
  272. Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I Study
  273. Nodular gastritis and Helicobacter pylori.
  274. Neutrophil activation by Helicobacter pylori.
  275. Absence of Benefit of Eradicating Helicobacter pylori in Patients with Nonulcer Dyspepsia
  276. The gastric cardia in Helicobacter pylori infection
  277. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis
  278. Helicobacter pylori and MALT Lymphom
  279. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model.
  280. The spatial orientation of Helicobacter pylori in the gastric mucus
  281. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori
  282. Therapy for Helicobacter pylori in Patients with Nonulcer Dyspepsia: A Meta-Analysis of Randomized, Controlled Trials
  283. I. Helicobacter pylori: Its epidemiology and its role in duodenal ulcer disease
  284. Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype
  285. A new highly effective short-term therapy schedule for Helicobacter pylori eradication.
  286. Grb2 Is a Key Mediator of Helicobacter pylori CagA Protein Activities
  287. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy
  288. Review article: the treatment of refractory Helicobacter pylori infection
  289. Beneficial Effects of Helicobacter pylori Eradication on Idiopathic Chronic Urticaria
  290. The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies
  291. Global burden of gastric cancer attributable to Helicobacterpylori
  292. Helicobacter pylori Colonization in Early Life
  293. Helicobacter pylori and Esophageal Cancer Risk: A Meta-analysis
  294. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease
  295. An Inverse Relation between cagA+ Strains of Helicobacter pylori Infection and Risk of Esophageal and Gastric Cardia Adenocarcinoma
  296. Helicobacter pylori infection in childhood: risk factors and effect on growth
  297. Risk Factors for Helicobacter pylori Resistance in the United States: The Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP) Study, 1993–1999
  298. Helicobacter pylori—Is It a Novel Causative Agent in Vitamin B12 Deficiency?
  299. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis
  300. Long-Term Follow-up of Voluntary Ingestion of Helicobacter pylori
  301. Distinctiveness of Genotypes of Helicobacter pylori in Calcutta, India
  302. Effect of Ranitidine and Amoxicillin plus Metronidazole on the Eradication of Helicobacter pylori and the Recurrence of Duodenal Ulcer
  303. Helicobacter pylori motility
  304. Natural Antibiotic Function of a Human Gastric Mucin Against Helicobacter pylori Infection
  305. Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis
  306. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans
  307. Mucosal Tumor Necrosis Factor-or, Interleukin-1/3, and Interleukin-8 Production in Patients with Helicobacter pylori Infection
  308. Non-human reservoirs of Helicobacter pylori.
  309. Helicobacter pylori virulence factors in gastric carcinogenesis
  310. Does Helicobacter pylori protect against asthma and allergy?
  311. Review article: the global emergence of Helicobacter pylori antibiotic resistance
  312. Endoscopic transmission of Helicobacter pylori
  313. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications
  314. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer.
  315. Relationship between Helicobacter pylori iceA, cagA, and vacA Status and Clinical Outcome: Studies in Four Different Countries
  316. Helicobacter pyloriINFECTION IN GASTRIC CANCEROGENES
  317. A Community-Based Seroepidemiologic Study of Helicobacter pylori Infection in Mexico
  318. Helicobacter pylori infection
  319. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity
  320. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia
  321. NF-κB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein
  322. Activities of Garlic Oil, Garlic Powder, and Their Diallyl Constituents against Helicobacter pylori
  323. Association of Helicobacter pylori infection with elevated serum lipids
  324. One week eradication regimen for Helicobacter pylori
  325. Meta-analysis: Can Helicobacter pylori Eradication Treatment Reduce the Risk for Gastric Cancer?
  326. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE study
  327. Helicobacter pylori: the size of the problem
  328. Helicobacter pylori cagA + Strains and Dissociation of Gastric Epithelial Cell Proliferation From Apoptosis
  329. Helicobacter pylori isolated from the domestic cat: public health implications.
  330. Cytokine gene expression in Helicobacter pylori associated antral gastritis.
  331. Induction of Gastric Epithelial Cell Apoptosis by Helicobacter pylori Vacuolating Cytotoxin
  332. Thyroxine in Goiter, Helicobacter pylori Infection, and Chronic Gastritis
  333. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review
  334. Treatment of Helicobacter pylori Reduces the Rate of Rebleeding in Peptic Ulcer Disease
  335. Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution
  336. Antibiotic resistance in Helicobacter pylori infection
  337. ChronicUrticariaandHelicobacterpylori
  338. Helicobacter pylori in Gambian children with chronic diarrhoea and malnutrition.
  339. Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils
  340. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection
  341. Protection against Helicobacter pylori and Other Bacterial Infections by Garlic
  342. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa
  343. Helicobacter pylori: a poor man’s gut pathogen?
  344. Dental Plaque: A Permanent Reservoir of Helicobacter pylori?
  345. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood
  346. Helicobacter pylori evolution and phenotypic diversification in a changing host
  347. Global Transposon Mutagenesis and Essential Gene Analysis of Helicobacter pylori
  348. Phenolic antioxidants from clonal oregano (Origanum vulgare) with antimicrobial activity against Helicobacter pylori
  349. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists
  350. Simple sequence repeats in the Helicobacter pylori genome
  351. Review article: exploring the link between Helicobacter pylori and gastric cancer
  352. Helicobacter pylori urease activity is toxic to human gastric epithelial cells.
  353. Cyclooxygenase-2 Expression in Helicobacter pylori-Associated Premalignant and Malignant Gastric Lesions
  354. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori.
  355. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro.
  356. Gastric Interleukin‐8 and IgA IL‐8 Autoantibodies in Helicobacter pylori Infection
  357. Helicobacter pylori and reflux disease
  358. Regulation of Gastric Carcinogenesis by Helicobacter pylori Virulence Factors
  359. Acid-Adaptive Genes of Helicobacter pylori
  360. IV. Helicobacter pylori and peptic ulceration: Histopathological aspects
  361. Determinants of Helicobacter pylori Infection and Chronic Gastritis.
  362. The Disease Spectrum of Helicobacter pylori: The Immunopathogenesis of Gastroduodenal Ulcer and Gastric Cancer
  363. Helicobacter pylori and Interleukin 1 Genotyping: An Opportunity to Identify High-Risk Individuals for Gastric Carcinoma
  364. Review article: pathogenesis of Helicobacter pylori‐induced gastric inflammation
  365. Virulence Factors of Helicobacter pylori Responsible for Gastric Diseases in Mongolian Gerbil
  366. Purification and N-terminal analysis of urease from Helicobacter pylori.
  367. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease.
  368. Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter pylori Eradication
  369. Differences in Genotypes of Helicobacter pylori from Different Human Populations
  370. What Role Does Helicobacter pylori Play in Gastric Cancer?
  371. Helicobacter mustelae-associated gastritis in ferrets
  372. Motility as a factor in the colonisation of gnotobiotic piglets by Helicobacter pylori
  373. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
  374. Helicobacter pylori Diagnosis and Management
  375. Extradigestive manifestations of Helicobacter pylori gastric infection
  376. High eradication rates of Helicobacter pylori with a new sequential treatment
  377. Reversal of Iron Deficiency Anemia after Helicobacter pylori Eradication in Patients with Asymptomatic Gastritis
  378. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium
  379. Age at Establishment of Helicobacter pylori Infection and Gastric Carcinoma, Gastric Ulcer, and Duodenal Ulcer Risk
  380. Helicobacter pylori genetic diversity within the gastric niche of a single human host
  381. Preventing Recurrent Upper Gastrointestinal Bleeding in Patients with Helicobacter pylori Infection Who Are Taking Low-Dose Aspirin or Naproxen
  382. Coccoid Forms of Helicobacter pylori in the Human Stomach
  383. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death.
  384. Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer.
  385. Helicobacter pylori genome evolution during human infection
  386. The life and death of Helicobacter pylori
  387. Helicobacter pylori infection: A clinical overview
  388. Antibacterial Activity of Hydrolyzable Tannins Derived from Medicinal Plants against Helicobacter pylori
  389. Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits
  390. Treatment of Helicobacter pylori Infection 2010
  391. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors
  392. Induction of host signal transduction pathways by Helicobacter pylori
  393. Selective Inhibition of Ii-dependent Antigen Presentation by Helicobacter pylori Toxin VacA
  394. Helicobacter pylori infection in children: potential clues to pathogenesis.
  395. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori
  396. CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines.
  397. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage
  398. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia
  399. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom
  400. Natural history of Helicobacter pylori infection
  401. The prevalence of Helicobacter pylori-positive serology in asymptomatic children.
  402. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen.
  403. Seroprevalence of Helicobacter pylori in Chile: Vegetables May Serve as One Route of Transmission
  404. Gastric lymphoid follicles in Helicobacter pylori infection: Frequency, distribution, and response to triple therapy
  405. Coccoid Helicobacter pylori Not Culturable In Vitro Reverts in Mice
  406. Relationship between Helicobacter pylori infection and Alzheimer disease
  407. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis
  408. Sequential Therapy for Helicobacter pylori Eradication: A Critical Review
  409. Pathogenesis of Helicobacter pylori Infection
  410. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response
  411. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis
  412. Helicobacter pylori: comparison of DNA fingerprints provides evidence for intrafamilial infection.
  413. The Epidemiology of Helicobacter pylori
  414. Pathobiology of Helicobacter pylori–Induced Gastric Cancer
  415. Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype.
  416. Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity.
  417. Pathogenic mechanisms of Helicobacter pylori.
  418. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients
  419. A new look at anti-Helicobacter pylori therapy
  420. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer
  421. Isolation and Genotyping of Helicobacter pylori from Untreated Municipal Wastewater
  422. Beneficial effects of Helicobacter pylori eradication on migraine.
  423. Helicobacter pylori‐Related Iron Deficiency Anemia: A Review
  424. Helicobacter pylori-Specific CD4+ CD25high Regulatory T Cells Suppress Memory T-Cell Responses to H. pylori in Infected Individuals
  425. The role of probiotics in the treatment and prevention of Helicobacter pylori infection
  426. Hypothesis: The Changing Relationships of Helicobacter pylori and Humans: Implications for Health and Disease
  427. Helicobacter pylori antibody and gastric carcinoma among young adults
  428. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease
  429. Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry?
  430. Helicobacter pylori: Pathology and Diagnostic Strategies
  431. Helicobacter pylori—in vitro susceptibility to garlic (Allium sativum) extract
  432. Helicobacter pylori eradication treatment reduces the severity of rosacea
  433. Helicobacter pylori
  434. Prospective screening of dyspeptic patients by Helicobacter pylori serology
  435. Gastric Lymphoma and Helicobacter pylori
  436. The Transmission of Helicobacter pylori. A Critical Review of the Evidence
  437. Role of cytokines in pathogenesis of Helicobacter pylori-induced mucosal damage.
  438. Helicobacter pylori Gastric Infection and Sideropenic
  439. Epidemiology of Helicobacter pylori in Southern China: Identification of Early Childhood as the Critical Period for Acquisition
  440. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease
  441. Src Is the Kinase of the Helicobacter pylori CagA Protein in Vitro and in Vivo
  442. Helicobacter pylori Flagellin Evades Toll-Like Receptor 5-Mediated Innate Immunity
  443. Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection
  444. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice
  445. Immunobiology of Helicobacter pylori infection
  446. Autoimmune Thrombocytopenic Purpura and Helicobacter pylori Infection
  447. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection
  448. Biofilm formation by Helicobacter pylori
  449. Epidemiology of Helicobacter pylori Infection
  450. Emergence of recombinant strains of Helicobacter pylori during human infection
  451. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites
  452. Helicobacter pylori and gastric acid: Biological and therapeutic implications
  453. Helicobacter pylori infection and dental care.
  454. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori
  455. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses
  456. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa
  457. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
  458. AN INTERNATIONAL ASSOCIATION BETWEEN HELICOBACTER-PYLORI INFECTION AND GASTRIC-CANCER.
  459. Comparative Genomics of Helicobacter pylori: Analysis of the Outer Membrane Protein Families
  460. In Vitro and In Vivo Activities of Tea Catechins against Helicobacter pylori
  461. Antimicrobial Activity of Essential Oils against Helicobacter pylori
  462. Cinnamon extracts’ inhibitory effect on Helicobacter pylori
  463. Adherence to gastric epithelial cells induces expression of a Helicobacter pylori gene, iceA, that is associated with clinical outcome.
  464. A New Helicobacter pylori Vacuolating Cytotoxin Determinant, the Intermediate Region, Is Associated With Gastric Cancer
  465. Helicobacter pylori Uses Motility for Initial Colonization and To Attain Robust Infection
  466. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China
  467. Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta‐analysis
  468. Helicobacter pylori reinfection with identical organisms: transmission by the patients’ spouses.
  469. Helicobacter pylori Infection in Skin Diseases
  470. Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition
  471. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection
  472. Smoking Increases the Treatment Failure for Helicobacter pylori Eradication
  473. Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure
  474. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer
  475. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori.
  476. Helicobacter pylori Persistence: an Overview of Interactions between H. pylori and Host Immune Defenses
  477. Isolation of Helicobacter pylori from dental plaques in healthy volunteers.
  478. Antibiotic resistance problems with Helicobacter pylori
  479. Helicobacter pylori Infection in the Colombian Andes: A Population-based Study of Transmission Pathways
  480. Seroprevalence of Helicobacter pylori infection in couples.
  481. Role of Helicobacter pylori in the Pathogenesis of Gastritis, Peptic Ulcer and Gastric Cancer
  482. Inducible Nitric Oxide Synthase, Nitrotyrosine, and Apoptosis in Helicobacter pylori Gastritis: Effect of Antibiotics and Antioxidants
  483. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?
  484. Chemokines in the gastric mucosa in Helicobacter pylori infection
  485. Helicobacter pylori Infection is the Major Risk Factor for Atrophic Gastritis.
  486. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial
  487. Why Helicobacter pylori has Lewis antigens
  488. Simultaneous visualization of Helicobacter pylori and gastric morphology: A new stain
  489. Diagnosis of Helicobacter pylori: Invasive and non-invasive tests
  490. Helicobacter pylori infection in children: clinical, endoscopic, and histologic correlations.
  491. Treatment of Helicobacter pylori
  492. Challenge model for Helicobacter pylori infection in human volunteers
  493. Effect of Proton-Pump Inhibitor Therapy on Diagnostic Testing for Helicobacter pylori
  494. Helicobacter pylori and peptic ulcers: the present position.
  495. Role of Helicobacter pylori Eradication in the Prevention of Peptic Ulcer Bleeding Relapse
  496. Mechanisms of Helicobacter pylori Infection: Bacterial Factors
  497. c‐Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs
  498. Helicobacter pylori Infection Enhances N-Methyl-N-nitrosourea-induced Stomach Carcinogenesis in the Mongolian Gerbil
  499. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1β production in Helicobacter pylori infection
  500. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia
  501. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice
  502. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication
  503. Heterogeneity of Helicobacter pylori.
  504. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
  505. Update on Helicobacter pylori Treatment.
  506. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.
  507. Characterization of Monospecies Biofilm Formation by Helicobacter pylori
  508. The Helicobacter pylori Vacuolating Toxin Inhibits T Cell Activation by Two Independent Mechanisms
  509. Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum.
  510. Detection of Helicobacter pylori in Stool Specimens by PCR and Antigen Enzyme Immunoassay
  511. Treatment of Helicobacter pylori
  512. Iron Deficiency and Helicobacter pylori Infection in the United States
  513. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism.
  514. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival
  515. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases
  516. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials
  517. Seven‐day therapy for Helicobacter pylori in the United States
  518. Review article: 13C‐urea breath test in the diagnosis of Helicobacter pylori infection – a critical review
  519. Helicobacter pylori Infection and Related Gastrointestinal Diseases
  520. Identification and Characterization of Helicobacter pylori Genes Essential for Gastric Colonization
  521. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies
  522. Rapid eradication of Helicobacter pylori infection
  523. The Interrelationship between Cytotoxin-Associated Gene A, Vacuolating Cytotoxin, and Helicobacter pylori-Related Diseases
  524. Hepatoprotective and anti-Helicobacter pylori activities of constituents from Brazilian propolis
  525. Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin.
  526. Helicobacter pylori in the Natural Environment
  527. Helicobacter pylori causes DNA damage in gastric epithelial cells
  528. Influence of Oral Helicobacter pylori on the Success of Eradication Therapy Against Gastric Helicobacter pylori
  529. In vitro selection of resistant Helicobacter pylori.
  530. Long-Term Follow-up of Helicobacter pylori Serology after Successful Eradication.
  531. The diverse antioxidant systems of Helicobacter pylori
  532. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms.
  533. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production.
  534. Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity.
  535. Prevalence of Helicobacter pylori–Associated Gastritis in Chronic Urticaria
  536. Surface localization of Helicobacter pylori urease and a heat shock protein homolog requires bacterial autolysis.
  537. Drug Therapy for Helicobacter pylori Infection: Problems and Pitfalls.
  538. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity.
  539. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates
  540. Relationship Between Helicobacter pylori Infection and Esophageal Neoplasia: A Meta-analysis
  541. Patient Factors Affecting Helicobacter pylori Eradication with Triple Therapy.
  542. Management Strategies for Helicobacter pylori-Seropositive Patients with Dyspepsia: Clinical and Economic Consequences
  543. Interleukin 1 Polymorphisms, Lifestyle Factors, and Helicobacter pylori Infection
  544. OralHelicobacter pylori: Can We Stomach It?
  545. Helicobacter pylori and gastric cancer
  546. PCR-based subtractive hybridization and differences in gene content among strains of Helicobacter pylori
  547. Effect of urease on HeLa cell vacuolation induced by Helicobacter pylori cytotoxin.
  548. Transmission of Helicobacter pylori Infection Studies in Families of Healthy Individuals
  549. Antimicrobial Resistance Incidence and Risk Factors among Helicobacter pylori–Infected Persons, United States
  550. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria
  551. Evidence-based Guidelines From ESPGHAN and NASPGHAN for Helicobacter pylori Infection in Children
  552. Familial clustering of Helicobacter pylori infection: population based studyCommentary: Helicobacter pylori—the story so far
  553. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.
  554. Extragastric Manifestations of Helicobacter pylori Infection
  555. PCR-based RFLP analysis of DNA sequence diversity in the gastric pathogen Helicobacter pylori
  556. Cellular vacuoles induced by Helicobacter pylori originate from late endosomal compartments
  557. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection
  558. Probiotics and Helicobacter pylori
  559. Antibacterial effect of plant extracts against Helicobacter pylori
  560. In Vitro and In Vivo Inhibition of Helicobacter pylori by Lactobacillus casei Strain Shirota
  561. Is Helicobacter pylori Infection a Necessary Condition for Noncardia Gastric Cancer?
  562. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man
  563. Role of Helicobacter pylori in the pathogenesis of atrophic gastritis.
  564. Rational Helicobacter pylori Therapy: Evidence-Based Medicine Rather Than Medicine-Based Evidence
  565. GASTRIC CANCER AND Helicobacter pylori INFECTION
  566. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis
  567. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells
  568. Helicobacter pylori GASTRITIS AND GASTRIC PHYSIOLOGY
  569. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori
  570. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease.
  571. SagA of CagA in Helicobacter pylori pathogenesis
  572. Difference in expression of Helicobacter pylori gastritis in antrum and body
  573. Construction of isogenic urease-negative mutants of Helicobacter pylori by allelic exchange.
  574. Not all Helicobacter pylori strains are created equal: should all be eliminated?
  575. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment—Helicobacter pylori positive (CADET-Hp) randomised controlled trial
  576. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease.
  577. Helicobacter pylori and Gastric Cancer: A New Paradigm For Inflammation-Associated Epithelial Cancers
  578. One week triple therapy for Helicobacter pylori: a multicentre comparative study
  579. Inhibitory effect of natural honey on Helicobacter pylori.
  580. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis
  581. Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction.
  582. Helicobacter pylori infection in functional dyspepsia
  583. Helicobacter pylori and Duodenal Ulcer Recurrence.
  584. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease.
  585. Helicobacter pylori–associated iron-deficiency anemia in adolescent female athletes
  586. The Design of Vaccines Against Helicobacter pylori and Their Development
  587. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia
  588. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial
  589. 7 – Phase Variation in Helicobacter pylori Lipopolysaccharide
  590. Relation between infection with Helicobacter pylori and living conditions in childhood: evidence for person to person transmission in early life
  591. Regulation of gastric epithelial cell growth by Helicobacter pylori: Offdence for a major role of apoptosis
  592. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses
  593. High Levels of Aberrant DNA Methylation in Helicobacter pylori–Infected Gastric Mucosae and its Possible Association with Gastric Cancer Risk
  594. Helicobacter pylori and extragastric diseases
  595. Is Helicobacter pylori the cause of dyspepsia?
  596. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori‐associated chronic idiopathic thrombocytopenic purpura
  597. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion
  598. Histological identification of Helicobacter pylori: comparison of staining methods
  599. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea
  600. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis
  601. Mucosal FOXP3-Expressing CD4+ CD25high Regulatory T Cells in Helicobacter pylori-Infected Patients
  602. pH-Regulated Gene Expression of the Gastric Pathogen Helicobacter pylori
  603. Therapy of Helicobacter pylori: current status and issues
  604. Helicobacter pylori infection: Detection, investigation, and management
  605. Catalase, a novel antigen for Helicobacter pylori vaccination.
  606. Helicobacter pylori infection and relation to gastric disease
  607. Secondary Resistance Among 554 Isolates of Helicobacter pylori After Failure of Therapy
  608. Helicobacter pylori–Related Disease
  609. Meta-analysis of Risk Factors for Peptic Ulcer: Nonsteroidal Antiinflammatory Drugs, Helicobacter pylori, and Smoking
  610. Helicobacter pylori infection in perforated peptic ulcer disease
  611. Helicobacter pylori infection and gastric cancer
  612. Gastric bacteria other than Helicobacter pylori.
  613. Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease.
  614. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury
  615. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
  616. Disease‐specific Helicobacter pylori Virulence Factors: The Unfulfilled Promise
  617. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains
  618. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production
  619. Helicobacter pylori infection and gastric cancer
  620. How Does Helicobacter pylori Cause Mucosal Damage? Direct Mechanisms
  621. Helicobacter pylori — Not a Good Bug after All
  622. Role of metronidazole resistance in therapy of Helicobacter pylori infections.
  623. Serum ferritin, hemoglobin, and Helicobacter pylori infection: A seroepidemiologic survey comprising 2794 Danish adults
  624. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori.
  625. Gastritis due to spiral shaped bacteria other than Helicobacter pylori: clinical, histological, and ultrastructural findings.
  626. An investigation into factors associated with Helicobacter pylori infection
  627. Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy.
  628. Gastric Dysplasia and Gastric Cancer: Helicobacter pylori, Serum Vitamin C, and Other Risk Factors
  629. Antimicrobial Activity of Curcumin against Helicobacter pylori Isolates from India and during Infections in Mice
  630. Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications
  631. Low rates of Helicobacter pylori reinfection in children
  632. Helicobacter pylori CagA Phosphorylation-Independent Function in Epithelial Proliferation and Inflammation
  633. Helicobacter pylori Eradication in Functional Dyspepsia
  634. How Should Helicobacter pylori Infection Be Diagnosed?
  635. Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides.
  636. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population
  637. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents–an evidence-based evaluation.
  638. A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates
  639. Helicobacter pylori in North and South America before Columbus
  640. Choosing the Best Anti-Helicobacter pylori Therapy: Effect of Antimicrobial Resistance.
  641. Treatment strategies for Helicobacter pylori infection.
  642. Direct polymerase chain reaction test for detection of Helicobacter pylori in humans and animals.
  643. Amoxycillin tolerance in Helicobacter pylori
  644. Epidemiology and diagnosis of Helicobacter pylori infection
  645. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri
  646. [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
  647. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis.
  648. Effects of Helicobacter pylori Eradication on Early Stage Gastric Mucosa–Associated Lymphoid Tissue Lymphoma
  649. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection.
  650. Helicobacter pylori Infection and Iron Stores: A Systematic Review and Meta‐analysis
  651. Antibacterial effect of garlic and omeprazole on Helicobacter pylori
  652. Use of autoradiography to assess viability of Helicobacter pylori in water.
  653. The Epidemiology of Helicobacter pylori in Peruvian Children between 6 and 30 Months of Age.
  654. MicroRNA signatures in Helicobacter pylori‐infected gastric mucosa
  655. Anti-Helicobacter pylori Agents from the Cashew Apple
  656. Iron acquisition by Helicobacter pylori: importance of human lactoferrin.
  657. Helicobacter pylori and gastric cancer
  658. Concordance of Helicobacter pylori Strains within Families
  659. Helicobacter pylori impairs iron absorption in infected individuals
  660. The Gastric Biology of Helicobacter pylori*
  661. Oral Carriage of Helicobacter pylori: A Review
  662. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production
  663. Helicobacter pylori induced apoptosis
  664. Helicobacter pylori gastritis—Epidemiology
  665. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review
  666. Detection of Helicobacter pylori gene expression in human gastric mucosa.
  667. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial
  668. Serodiagnosis of Helicobacter pylori: comparison of enzyme-linked immunosorbent assays.
  669. Inactivation of Helicobacter pylori by chlorination.
  670. Effect of Helicobacter pylori eradication on sideropenic refractory anaemia in adolescent girls with Helicobacter pylori infection
  671. Long-Term Course and Consequences of Helicobacter pylori gastritis Results of a 32-Year Follow-up Study
  672. Density of Helicobacter pylori Infection In Vivo as Assessed by Quantitative Culture and Histology
  673. Helicobacter pylori virulence factors—one part of a big picture
  674. CD25+/Foxp3+ T Cells Regulate Gastric Inflammation and Helicobacter pylori Colonization In Vivo
  675. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up
  676. Improvement in Atrophic Gastritis and Intestinal Metaplasia in Patients in Whom Helicobacter pylori Was Eradicated
  677. Epidemiology of Helicobacter pylori infection
  678. Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment
  679. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa.
  680. Effect of Helicobacter pylori and its eradication on gastric juice ascorbic acid.
  681. Salty Food Intake and Risk of Helicobacter pylori Infection
  682. Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection
  683. Gastric epithelium in the duodenum: its association with Helicobacter pylori and inflammation.
  684. Horizontal versus Familial Transmission of Helicobacter pylori
  685. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein
  686. Elimination of Helicobacter pylori under treatment with omeprazole.
  687. Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus
  688. Association between Helicobacter pylori Infection and Pancreatic Cancer
  689. Bugs on trial: the case of Helicobacter pylori and autoimmunity
  690. Helicobacter pylori Infection and Gastric Adenocarcinoma
  691. Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides.
  692. Survival of Helicobacter pylori in a Natural Freshwater Environment
  693. The link between Helicobacter pylori infection and rosacea
  694. Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality
  695. Helicobacter pylori virulence factors: facts and fantasies
  696. Acid Acclimation by Helicobacter pylori
  697. Cag pathogenicity island-specific responses of gastric epithelial cells to Helicobacter pylori infection
  698. Bactericidal Activity of Pistacia lentiscus Mastic Gum Against Helicobacter pylori
  699. The prevalence of Helicobacter pylori infection in gastric cancer.
  700. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45.
  701. Diagnosis of Helicobacter pylori infection
  702. Helicobacter pylori infection and gastric lymphoma
  703. Gastric T lymphocyte responses to Helicobacter pylori in patients with H pylori colonisation.
  704. In vitro inhibition of Helicobacter pylori by extracts of thyme
  705. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group
  706. Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations.
  707. Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori?
  708. Meta-analysis: Duration of First-Line Proton-Pump Inhibitor–BasedTriple Therapy forHelicobacter pyloriEradication
  709. Helicobacter pylori-induced gastritis in the domestic cat.
  710. Helicobacter pylori enter and survive within multivesicular vacuoles of epithelial cells
  711. High prevalence of Helicobacter pylori in saliva demonstrated by a novel PCR assay.
  712. Helicobacter pylori Urease: Properties and Role in Pathogenesis
  713. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori
  714. A Comprehensive Review of the Natural History of Helicobacter pylori Infection in Children
  715. Molecular Characterization of Two-Component Systems of Helicobacter pylori
  716. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study
  717. BCA-1 is highly expressed in Helicobacter pylori–induced mucosa-associated lymphoid tissue and gastric lymphoma
  718. Effect of Pretreatment Antibiotic Resistance to Metronidazole and Clarithromycin on Outcome of Helicobacter pylori Therapy
  719. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations?
  720. In vitro anti-Helicobacter pylori activity of Greek herbal medicines
  721. DISCOVERY BY JAWORSKI OF Helicobacter pyloriAND ITS PATHOGENETIC ROLE IN PEPTIC ULCER, GASTRITIS AND GASTRIC CANCER
  722. Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis
  723. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study
  724. Helicobacter pylori eradication therapy
  725. Structure of the Neutrophil-activating Protein from Helicobacter pylori
  726. Lactobacillus acidophilus Autolysins Inhibit Helicobacter pylori In Vitro
  727. Expression of 120 kilodalton protein and cytotoxicity in Helicobacter pylori.
  728. Helicobacter pylori Strain-specific Genotypes and Modulation of the Gastric Epithelial Cell Cycle
  729. VacA from Helicobacter pylori: a hexameric chloride channel
  730. Free-living Amoebae Promote Growth and Survival of Helicobacter pylori
  731. Occurrence of Helicobacter pylori in surface water in the United States
  732. Helicobacter pylori and molecular events in precancerous gastric lesions
  733. Analysis and typing of the vacA gene from cagA-positive strains of Helicobacter pylori isolated in Japan.
  734. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes
  735. Metronidazole resistance in Helicobacter pylori
  736. GASTRIC PATHOLOGY ASSOCIATED WITH Helicobacter pylori
  737. Ulcer risk factors: Interactions between Helicobacter pylori infection, nonsteroidal use, and age
  738. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men.
  739. Helicobacter pylori among Preschool Children and Their Parents: Evidence of Parent-Child Transmission
  740. Canadian Helicobacter pylori Consensus Conference Update: Infections in Adults
  741. Relationship between Helicobacter pylori infection and glaucoma
  742. Gain and Loss of Multiple Genes During the Evolution of Helicobacter pylori
  743. The Neutrophil-Activating Protein (Hp-Nap) of Helicobacter pylori Is a Protective Antigen and a Major Virulence Factor
  744. Early Helicobacter pylori Eradication Decreases Risk of Gastric Cancer in Patients With Peptic Ulcer Disease
  745. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett’s oesophagus.
  746. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
  747. Pathogenesis of Helicobacter pylori Infection
  748. Helicobacter pylori Gastritis in Children Is Associated With a Regulatory T-Cell Response
  749. Helicobacter pylori-associated gastroduodenal disease in childhood.
  750. Probiotics and Helicobacter pylori eradication
  751. Unique cholesteryl glucosides in Helicobacter pylori: composition and structural analysis.
  752. Disappearance of Hyperplastic Polyps in the Stomach after Eradication of Helicobacter pylori: A Randomized, Controlled Trial
  753. Tolerance Rather Than Immunity Protects From Helicobacter pylori–Induced Gastric Preneoplasia
  754. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe
  755. Helicobacter pylori: present status and future prospects in Japan
  756. Intact Gram-Negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus Bacteria Activate Innate Immunity via Toll-Like Receptor 2 but Not Toll-Like Receptor 4
  757. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
  758. Management of Helicobacter pylori infection.
  759. Selective increase of the permeability of polarized epithelial cell monolayers by Helicobacter pylori vacuolating toxin.
  760. Acid survival of Helicobacter pylori: how does urease activity trigger cytoplasmic pH homeostasis?
  761. Helicobacter pylori Physiology Predicted from Genomic Comparison of Two Strains
  762. Cure of Helicobacter pylori Infection and Duration of Remission of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
  763. Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: a Systematic Review
  764. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis
  765. Helicobacter pylori and the Birth Cohort Effect: Evidence of a Continuous Decrease of Infection Rates in Childhood.
  766. Metabolism and Genetics of Helicobacter pylori: the Genome Era
  767. Helicobacter pylori infection in children: relation with current household living conditions.
  768. Helicobacter pylori-coccoid forms and biofilm
  769. Prevention of ulcer recurrence after eradication of Helicobacter pylori: A prospective long-term follow-up study
  770. The inflammatory and immune response to Helicobacter pylori infection
  771. Helicobacter pylori infection with iron deficiency anaemia and subnormal growth at puberty
  772. Helicobacter pylori infection and growth delay in older children
  773. Low Prevalence of Helicobacter pylori‐negative Gastric Cancer among Japanese
  774. Chronic Helicobacter pylori infections induce gastric mutations in mice
  775. Reversal of Long-Standing Iron Deficiency Anaemia after Eradication of Helicobacter pylori Infection
  776. Treatment of Helicobacter pylori
  777. Typing of Helicobacter pylori vacA Gene and Detection of cagA Gene by PCR and Reverse Hybridization
  778. Epidemiology and diagnosis of Helicobacter pylori infection
  779. Importance of Helicobacter pylori cagA and vacAstatus for the efficacy of antibiotic treatment
  780. Helicobacter pylori: an invading microorganism? A review
  781. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese
  782. Gastric Atrophy and Intestinal Metaplasia before and after Helicobacter pylori Eradication: A Meta-Analysis
  783. Age of the Association between Helicobacter pylori and Man
  784. The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: Evolution during disease progression
  785. Cloning and genetic characterization of the Helicobacter pylori and Helicobacter mustelae flaB flagellin genes and construction of H. pylori flaA- and flaB-negative mutants by electroporation-mediated allelic exchange.
  786. Tooth loss, pancreatic cancer, and Helicobacter pylori
  787. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations.
  788. Population genetic analysis of Helicobacter pylori by multilocus enzyme electrophoresis: extensive allelic diversity and recombinational population structure.
  789. Helicobacter pylori was recovered from sheep milk, suggesting a role for animals in transmission. H pylori may be a commensal in the sheep, which may be H pylori’s ancestral host.
  790. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro
  791. Helicobacter pylori Associated with Glossitis and Halitosis
  792. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer.
  793. Resveratrol inhibits the growth of Helicobacter pylori in vitro
  794. Human milk kappa-casein and inhibition of Helicobacter pylori adhesion to human gastric mucosa.
  795. Helicobacter pylori: The Mouth, Stomach, and Gut Axis
  796. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia?
  797. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation
  798. Asthma Is Inversely Associated with Helicobacter pylori Status in an Urban Population
  799. Helicobacter pylori Membrane Protein 1: A New Carcinogenic Factor of Helicobacter pylori
  800. Geographic Differences in Gastric Cancer Incidence Can be Explained by Differences between Helicobacter pylori Strains
  801. Vacuoles Induced by Helicobacter pylori Toxin Contain Both Late Endosomal and Lysosomal Markers
  802. Effect of Treatment of Helicobacter pylori Infection on Rosacea
  803. Helicobacter pylori and Socioeconomic Factors in Russia
  804. Smoking and peptic ulcer in the Helicobacter pylori era.
  805. Prevalence of Helicobacter pylori Infection Worldwide: A Systematic Review of Studies with National Coverage
  806. Epidemiology of Helicobacter pylori Infection
  807. The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections
  808. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome
  809. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer
  810. Analysis of the genetic diversity of Helicobacter pylori: the tale of two genomes
  811. Localization of Helicobacter pylori urease and heat shock protein in human gastric biopsies.
  812. The Role of T Cell Subsets and Cytokines in the Pathogenesis of Helicobacter pylori Gastritis in Mice
  813. Helicobacter pylori infection in pernicious anemia: A prospective controlled study
  814. Eradication of Helicobacter pylori Infection
  815. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole
  816. Helicobacter pylori and peptic ulcer disease.
  817. Lewis antigens in Helicobacter pylori: biosynthesis and phase variation
  818. Helicobacter pylori infection among offspring of patients with stomach cancer
  819. Helicobacter pylori Factors Associated With Disease Development
  820. The Versatility of Helicobacter pylori CagA Effector Protein Functions: The Master Key Hypothesis
  821. A urease-negative mutant of Helicobacter pylori constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach.
  822. Role of Innate Immunity in Helicobacter pylori-Induced Gastric Malignancy
  823. Consequences of Helicobacter pylori infection in children
  824. Helicobacter pylori Infection Is Markedly Increased in Patients With Autoimmune Atrophic Thyroiditis
  825. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry
  826. Hyperammonaemia and Helicobacter pylori
  827. The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic Review
  828. Helicobacter pylori: a ROS-inducing bacterial species in the stomach
  829. Randomized Placebo‐Controlled Trial of Helicobacter pylori Eradication for Iron‐Deficiency Anemia in Preadolescent Children and Adolescents
  830. Hydrogen uptake hydrogenase in Helicobacter pylori
  831. Vacuolating Cytotoxin of Helicobacter pylori Plays a Role during Colonization in a Mouse Model of Infection
  832. The Mother as Source of Helicobacter pylori Infection
  833. Levofloxacin based regimens for the eradication of Helicobacter pylori
  834. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class.
  835. In Vitro Activity of Olive Oil Polyphenols against Helicobacter pylori
  836. Use Caution with Serologic Testing for Helicobacter pylori Infection in Children
  837. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy
  838. Test device and kit for detecting Helicobacter pylori
  839. Crystal Structure of the Hexameric Traffic ATPase of the Helicobacter pylori Type IV Secretion System
  840. Long‐term follow‐up of gastric histology after Helicobacter pylori eradication
  841. Prevalence of Helicobacter pylori infection in children (south of Iran)
  842. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.
  843. Complete Remission of Primary High-Grade B-Cell Gastric Lymphoma After Cure of Helicobacter pylori Infection
  844. Association of symptoms with Helicobacter pylori infection in children
  845. Helicobacter pylori infection and food-cobalamin malabsorption
  846. Construction of a Helicobacter pylori genome map and demonstration of diversity at the genome level.
  847. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori
  848. Transmission of Helicobacter pylori infection.
  849. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990–1999)
  850. Diagnostic Tests for Helicobacter pylori: A Prospective Evaluation of Their Accuracy, without Selecting a Single Test as the Gold Standard.
  851. Helicobacter pylori and the gastric microbiota
  852. Genetic diversity of Helicobacter pylori
  853. Improved Efficacy of 10-Day Sequential Treatment for Helicobacter pylori Eradication in Children: A Randomized Trial
  854. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori
  855. Helicobacter pylori in the oral cavity: A critical review of the literature
  856. Helicobacter pylori is killed by nitrite under acidic conditions
  857. Intracellular, Intercellular, and Stromal Invasion of Gastric Mucosa, Preneoplastic Lesions, and Cancer by Helicobacter pylori
  858. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection
  859. Helicobacter pylori CagA and Gastric Cancer: A Paradigm for Hit-and-Run Carcinogenesis
  860. In Vitro susceptibility of Helicobacter pylori to botanical extracts used traditionally for the treatment of gastrointestinal disorders
  861. Helicobacter pylori infection and cancer
  862. Detection of Helicobacter pylori in oral aphthous ulcers
  863. Helicobacter pylori infection and insulin-dependent diabetes mellitus
  864. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
  865. Hyperemesis Gravidarum and Helicobacter pylori Infection: A Systematic Review
  866. Impact of Metronidazole Resistance on the Eradication of Helicobacter pylori
  867. Neutrophil Activation by Helicobacter pylori Lipopolysaccharides
  868. Helicobacter pylori sero-prevalence in asthma
  869. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial
  870. Virulent Strains of Helicobacter pylori Demonstrate Delayed Phagocytosis and Stimulate Homotypic Phagosome Fusion in Macrophages
  871. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis
  872. Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL‐8 in gastric epithelial cells
  873. Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pylori
  874. Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility
  875. Helicobacter pylori culture and antimicrobial resistance in Iran
  876. Long-term colonization with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting.
  877. Helicobacter pylori seropositivity in patients with hyperemesis gravidarum
  878. A Century of Helicobacter pylori
  879. Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study
  880. Towards deciphering the Helicobacter pylori cytotoxin
  881. Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age.
  882. Conservation, localization and expression of HopZ, a protein involved in adhesion of Helicobacter pylori
  883. Inhibition of T-Cell Proliferation by Helicobacter pylori γ-Glutamyl Transpeptidase
  884. Pathogenic Properties of Helicobacter pylori
  885. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma
  886. “Rescue” regimens after Helicobacter pylori treatment failure
  887. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis.
  888. Detection of Helicobacter pylori in gastric biopsy and resection specimens.
  889. Helicobacter pylori: seroprevalence and colorectal cancer.
  890. Relationship between the cagA 3′ repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH
  891. The Translation of Helicobacter pylori Basic Research to Patient Care
  892. Molecular epidemiology, population genetics, and pathogenic role of Helicobacter pylori
  893. Growth Phase-Dependent Response of Helicobacter pylori to Iron Starvation
  894. Stimulation of interleukin-8 production in epithelial cell lines by Helicobacter pylori.
  895. Accurate Diagnosis of Helicobacter pylori: Urease Tests
  896. Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis
  897. Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany
  898. Capsaicin as an inhibitor of the growth of the gastric pathogen Helicobacter pylori
  899. Mutation as an origin of genetic variability in Helicobacter pylori
  900. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe
  901. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori–is Helicobacter pylori a pathogenic factor in Ménétrier’s disease?
  902. Results from the Pediatric European Register for Treatment of Helicobacter pylori (PERTH)
  903. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen‐insensitive NADPH nitroreductase
  904. Pathogenesis of Helicobacter pylori Infection
  905. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration.
  906. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux.
  907. Urea breath tests in the management of Helicobacter pylori infection
  908. Human and Helicobacter pylori coevolution shapes the risk of gastric disease
  909. Treatment of Helicobacter pylori Infection 2011
  910. Production of a Cytotoxin by Helicobacter pylori
  911. Impaired Production of Gastric Ghrelin in Chronic Gastritis Associated with Helicobacter pylori
  912. Helicobacter pylori factors associated with disease
  913. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
  914. Rifabutin‐based Helicobacter pylori eradication ‘rescue therapy’
  915. Helicobacter pylori Phenotypes Associated with Peptic Ulceration
  916. Immunomagnetic separation and PCR for detection of Helicobacter pylori in water and stool specimens.
  917. Central Serous Chorioretinopathy and Helicobacter pylori
  918. Chemotactic activity of Helicobacter pylori sonicate for human polymorphonuclear leucocytes and monocytes.
  919. The Relationship Between Consumption of Antimicrobial Agents and the Prevalence of Primary Helicobacter pylori Resistance
  920. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus
  921. Helicobacter pylori and Chronic ITP
  922. Identification, characterization, and spatial localization of two flagellin species in Helicobacter pylori flagella.
  923. Iron deficiency anaemia and Helicobacter pylori infection
  924. Helicobacter pylori Reinfection Is Virtually Absent after Successful Eradication
  925. Survival of Helicobacter pylori in milk and tap water
  926. Identification of Helicobacter pylori Biofilms in Human Gastric Mucosa
  927. The effect of environmental pH on the proton motive force of Helicobacter pylori
  928. Treatment of Helicobacter pylori infection and factors influencing eradication
  929. Structural characterization of the lipid A component of Helicobacter pylori rough- and smooth-form lipopolysaccharides.
  930. Linking Helicobacter pylori to gastric cancer
  931. Helicobacter pylori infection rates in relation to age and social class in a population of Welsh men.
  932. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study
  933. Helicobacter pyloriThe Etiologic Agent for Peptic Ulcer
  934. Review article Is Helicobacter pylori transmitted by the gastro‐oral route?
  935. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori.
  936. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication
  937. Abstract 4269: Regulation and functional roles of autophagy in Helicobacter pylori CagA-mediated gastric cancer
  938. Diagnosis and treatment of Helicobacter pylori in adults with an intellectual disability
  939. Prevalence of Helicobacter pylori infection and antibiotic resistance profile in Armenia
  940. Real-time PCR detection of a 16S rRNA single mutation of Helicobacter pylori isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts
  941. Pharmaceutical compositions for the treatment of Helicobacter pylori
  942. Maturation of atypical ribosomal RNA precursors in Helicobacter pylori
  943. Helicobacter pylori lipids can form ordered membrane domains (rafts)
  944. Classification of Helicobacter pylori Virulence Factors: Is CagA a Toxin or Not?
  945. A DNAzyme‐Based Colorimetric Paper Sensor for Helicobacter pylori
  946. Noninvasive Diagnostic Tests for Helicobacter pylori Infection
  947. Review: Helicobacter pylori and extragastric diseases
  948. Does Eradication of Helicobacter pylori Cause Inflammatory Bowel Disease?
  949. Helicobacter pylori senses bleach (HOCl) as a chemoattractant using a cytosolic chemoreceptor
  950. 45 – Helicobacter pylori Infection
  951. Iron status determination in individuals with Helicobacter pylori infection: conventional vs. new laboratory biomarkers
  952. Helicobacter pylori Vacuolating Cytotoxin A Causes Anorexia and Anxiety via Hypothalamic Urocortin 1 in Mice
  953. Review: Diagnosis of Helicobacter pylori infection
  954. Inhibition of polarity-regulating kinase PAR1b contributes to Helicobacter pylori inflicted DNA Double Strand Breaks in gastric cells
  955. The Helicobacter pylori HopQ outermembrane protein inhibits immune cell activities
  956. Helicobacter pylori infection promotes autophagy through Nrf2-mediated heme oxygenase upregulation in human gastric cancer cells
  957. PTU-067 Helicobacter pylori resistance: a complex socioeconomic problem?
  958. Helicobacter pylori infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection
  959. The core genome m5C methyltransferase JHP1050 (M.Hpy99III) plays an important role in orchestrating gene expression in Helicobacter pylori
  960. Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication
  961. Helicobacter pylori Deregulates T and B Cell Signaling to Trigger Immune Evasion
  962. How many protein molecules are secreted by single Helicobacter pylori cells: Quantification of serine protease HtrA
  963. Pathogenic potential of Helicobacter pylori strains can explain differences in H. pylori associated diseases rates from Chile and Cuba
  964. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics
  965. Effect of environmental salt concentration on the Helicobacter pylori exoproteome
  966. Comparative proteomics of Helicobacter pylori strains reveals geographical features rather than genomic variations
  967. A Genome-Wide Helicobacter pylori Morphology Screen Uncovers a Membrane-Spanning Helical Cell Shape Complex
  968. Development of a loop-mediated isothermal amplification assay for rapid Helicobacter pylori detection
  969. Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps
  970. Mechanisms of Inflammasome Signaling, microRNA Induction and Resolution of Inflammation by Helicobacter pylori
  971. Helicobacter pylori Infection
  972. Utilization Rate of Helicobacter pylori Immunohistochemistry Is Not Associated With the Diagnostic Rate of Helicobacter pylori Infection
  973. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018
  974. Impact of Helicobacter pylori and/or Helicobacter pylori–related metabolic syndrome on incidence of all-cause and Alzheimer’s dementia
  975. Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit
  976. Structural insights into the AapA1 toxin of Helicobacter pylori
  977. Review: Treatment of Helicobacter pylori Infection 2019
  978. α-Difluoromethylornithine reduces gastric carcinogenesis by causing mutations in Helicobacter pylori cagY
  979. Update of primary Helicobacter pylori resistance to antimicrobials in Brussels, Belgium
  980. Helicobacter pylori Induces IL-33 Production and Recruits ST-2 to Lipid Rafts to Exacerbate Inflammation
  981. Helicobacter pylori infection and risk of preeclampsia: a systematic review and meta-analysis
  982. Helicobacter pylori‐activated gastric fibroblasts induce epithelial‐mesenchymal transition of gastric epithelial cells in vitro in a TGF‐β‐dependent manner
  983. Halitosis: Helicobacter pylori or oral factors
  984. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infectionEfficacité d’un traitement d’éradication guidé par PCR pour le traitement de l’infection par Helicobacter pylori
  985. High-resolution mapping reveals that microniches in the gastric glands control Helicobacter pylori colonization of the stomach
  986. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis.
  987. Structure of the Helicobacter pylori Cag type IV Secretion System
  988. Amoxicillin sensitization rate in patients with eruptions after Helicobacter pylori eradication therapy
  989. Systematic review with meta‐analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease
  990. Helicobacter pylori treatment in Turkey: Current status and rational treatment options
  991. Targeted mobilization of Lrig1+ gastric epithelial stem cell populations by a carcinogenic Helicobacter pylori type IV secretion system
  992. Treatment of Helicobacter pylori
  993. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population‐based ESTHER cohort study
  994. Extract of Helicobacter pylori Ameliorates Parameters of Airway Inflammation and Goblet Cell Hyperplasia following Repeated Allergen Exposure
  995. Crystal structure of CagV, the Helicobacter pylori homologue of the T4SS protein VirB8
  996. Nod1 Imprints Inflammatory and Carcinogenic Responses toward the Gastric Pathogen Helicobacter pylori
  997. Recognition of Helicobacter pylori by protein‐targeting aptamers
  998. Nonhelical Helicobacter pylori Mutants Show Altered Gland Colonization and Elicit Less Gastric Pathology than Helical Bacteria during Chronic Infection
  999. The lipoprotein HP1454 of Helicobacter pylori regulates T‐cell response by shaping T‐cell receptor signalling
  1000. The Sweeping Role of Cholesterol Depletion in the Persistence of Helicobacter pylori Infections
  1001. Factors Associated With Adherence to Helicobacter pylori Testing During Hospitalization for Bleeding Peptic Ulcer Disease
  1002. CagA Effector Protein in Helicobacter pylori-Infected Human Gastric Epithelium in Vivo: From Bacterial Core and Adhesion/Injection Clusters to Host Cell Proteasome-Rich Cytosol
  1003. In Situ Molecular Architecture of the Helicobacter pylori Cag Type IV Secretion System
  1004. Synergistic effect of photodynamic therapy at 400 nm and doxycycline against Helicobacter pylori
  1005. Role of a Stem-Loop Structure in Helicobacter pylori cagA Transcript Stability
  1006. ADP heptose, a novel pathogen-associated molecular pattern identified in Helicobacter pylori
  1007. Establishment of serine protease htrA mutants in Helicobacter pylori is associated with secA mutations
  1008. Susceptibility-guided therapy for Helicobacter pylori infection treatment failure
  1009. Induction of CD44 Variant Isoforms is an Early Epithelial Response to Helicobacter pylori Infection
  1010. Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase
  1011. Expression of CEACAM1 or CEACAM5 in AZ‐521 cells restores the type IV secretion deficiency for translocation of CagA by Helicobacter pylori
  1012. CHAC1 overexpression in human gastric parietal cells with Helicobacter pylori infection in the secretory canaliculi
  1013. Structural Analysis of Helicobacter pylori VacA Reveals Insights into Oligomerization
  1014. Hepatoma-derived growth factor participates in Helicobacter pylori-induced neutrophils recruitment, gastritis and gastric carcinogenesis
  1015. Gastric adenocarcinoma of fundic gland type after Helicobacter pylori eradication: A case report
  1016. Helicobacter pylori in relation to asthma and allergy modified by abdominal obesity: The HUNT study in Norway
  1017. Effects of Anti–Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases
  1018. Varying pH influences the motility of Helicobacter pylori more strongly in porcine gastric mucin solutions than in broth.
  1019. Mutated Rnf43 Aggravates Helicobacter pylori-Induced Gastric Pathology
  1020. Epstein-Barr virus detection using gastric biopsy specimens after rapid urease test for Helicobacter pylori
  1021. Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection
  1022. New Perspectives in Gastric Cancer: Helicobacter pylori-Uninfected Pure Signet Ring Cell Carcinoma
  1023. Intracellular Degradation of Helicobacter pylori VacA Toxin as a Determinant of Gastric Epithelial Cell Viability
  1024. Evaluation of Lineage Changes in the Gastric Mucosa Following Infection With Helicobacter pylori and Specified Intestinal Flora in INS-GAS Mice
  1025. Potential roles of Helicobacter pylori treatment, body mass index and waist circumference in the causation of erosive esophagitis: a randomized clinical trial (HEROES-GERD)
  1026. Helicobacter pylori
  1027. Association Between Helicobacter pylori Infection and Short-segment/Long-segment Barrett’s Esophagus in a Japanese Population: A Large Cross-Sectional Study.
  1028. Geometric localization of cell wall growth and shape determining proteins in Helicobacter pylori
  1029. Helicobacter pylori Pathophysiology
  1030. Malignant Helicobacter pylori-Associated Diseases: Gastric Cancer and MALT Lymphoma
  1031. Helicobacter pylori Infection
  1032. Review: Pathogenesis of Helicobacter pylori infection
  1033. Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori
  1034. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial
  1035. Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword
  1036. Helicobacter pylori and Related Virulence Factors for Gastrointestinal Diseases
  1037. Both diet and Helicobacter pylori infection contribute to atherosclerosis in pre- and postmenopausal cynomolgus monkeys
  1038. Cryo-EM Analysis Reveals Structural Basis of Helicobacter pylori VacA Toxin Oligomerization
  1039. Relative potency of proton‐pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double‐dose PPI
  1040. Helicobacter pylori Exploits the NLRC4 Inflammasome to Dampen Host Defenses
  1041. Helicobacter pylori infection and prevalence of stroke
  1042. Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination
  1043. CAPZA1 determines the risk of gastric carcinogenesis by inhibiting Helicobacter pylori CagA-degraded autophagy
  1044. Specific high affinity interaction of Helicobacter pylori CagL with integrin αVβ6 promotes type IV secretion of CagA into human cells
  1045. pH-dependent gating mechanism of the Helicobacter pylori urea channel revealed by cryo-EM
  1046. Low‐level primary clarithromycin resistance of Helicobacter pylori in Burkina Faso: A prospective molecular study
  1047. Helicobacter pylori infection and gastroduodenal lesions in patients with systemic lupus erythematosus
  1048. CDX1 Expression Induced by CagA-Expressing Helicobacter pylori Promotes Gastric Tumorigenesis
  1049. Association between parental history of Helicobacter pylori treatment failure and treatment failure in the offspring
  1050. Interleukin-21 (IL-21) Downregulates Dendritic Cell Cytokine Responses to Helicobacter pylori and Modulates T Lymphocyte IL-17A Expression in Peyer’s Patches during Infection
  1051. Cryo-EM structures of Helicobacter pylori vacuolating cytotoxin A oligomeric assemblies at near-atomic resolution
  1052. Effect of Helicobacter pylori chemotaxis on gastric epithelial repair
  1053. Gastric Mucosal Microarchitectures Associated with Irreversibility with Helicobacter pylori Eradication and Downregulation of Micro RNA (miR)
  1054. Abstract 173: Helicobacter pylori Infection Increases the Risk for Carotid Atherosclerosis
  1055. Biochemical characterization of the Helicobacter pylori bactofilin-homolog HP1542
  1056. Activity and Functional Importance of Helicobacter pylori Virulence Factors
  1057. A Novel View of Human Helicobacter pylori Infections: Interplay between Microbiota and Beta-Defensins
  1058. Potential impact of Helicobacter pylori-induced optic neurodegeneration on MS patients
  1059. A pH-sensitive excited state intramolecular proton transfer fluorescent probe for imaging mitochondria and Helicobacter pylori
  1060. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance
  1061. Egyptian recommendations for management of Helicobacter pylori infection: 2018 report.
  1062. Probiotic Lactobacillus spp. Act Against Helicobacter pylori-induced Inflammation
  1063. Abstract 16244: Helicobacter pylori Infection Impairs Endothelial Function Through Exosome-Mediated Mechanism
  1064. Association Between Helicobacter pylori Exposure and Decreased Odds of Eosinophilic Esophagitis—A Systematic Review and Meta-analysis
  1065. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal
  1066. NOD1 mediates non-canonical inflammasome processing of interleukin-18 in epithelial cells to Helicobacter pylori infection
  1067. MEK Inhibitor Reverses Metaplasia and Allows Re-Emergence of Normal Lineages in Helicobacter pylori–Infected Gerbils
  1068. Helicobacter pylori resistance to current therapies
  1069. IN VITROANTI-Helicobacter pyloriAND ANTIMYCOBACTERIAL ACTIVITY EVALUATION OF PLANTS FROM TURKEY
  1070. MCOLN1/TRPML1 inhibition – a novel strategy used by Helicobacter pylori to escape autophagic killing and antibiotic eradication therapy in vivo
  1071. Helicobacter pylori VacA Targets Myeloid Cells in the Gastric Lamina Propria To Promote Peripherally Induced Regulatory T-Cell Differentiation and Persistent Infection
  1072. Helicobacter pylori virulence genes
  1073. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam
  1074. Helicobacter pylori eradication improves glycemic control in type 2 diabetes patients with asymptomatic active Helicobacter pylori infection
  1075. Molecular Basis of Unexpected Specificity of ABC Transporter-Associated Substrate-Binding Protein DppA from Helicobacter pylori
  1076. ASSOCIATION BETWEEN PROTEINURIA AND ACTIVE Helicobacter pylori INFECTION IN NON-DIABETIC PATIENTS
  1077. Increasing Testing for Helicobacter pylori Infection to Improve Quality of Patient Care
  1078. Methods for treating Helicobacter pylori infection
  1079. Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA
  1080. Correlation between Helicobacter pylori Infection and Gastric Atrophy Examined in the Sera of Mongolian People
  1081. Recruitment of CCR6+ Foxp3+ regulatory gastric infiltrating lymphocytes in Helicobacter pylori gastritis
  1082. Preparation Method of Outer Core Octasaccharide of Helicobacter pylori Lipopolysaccharide
  1083. Tropism for Spasmolytic Polypeptide-Expressing Metaplasia Allows Helicobacter pylori to Expand Its Intragastric Niche
  1084. The frequency of circulating integrin α4β7+ cells correlates with protection against Helicobacter pylori infection in immunized mice
  1085. Th17 Cells in Helicobacter pylori Infection: a Dichotomy of Help and Harm
  1086. Helicobacter pylori Genetic Polymorphisms in Gastric Disease Development
  1087. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain
  1088. Prediction of Novel Host-Pathogen Interactions for Helicobacter pylori Through Interface Mimicry and their Implications to Gastric Cancer
  1089. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay
  1090. Transmaternal Helicobacter pylori exposure reduces allergic airway inflammation in offspring through regulatory T cells
  1091. Review: Helicobacter pylori in pediatrics
  1092. Loss of a Cardiolipin Synthase in Helicobacter pylori G27 Blocks Flagellum Assembly
  1093. Risk factors for reflux esophagitis after eradication of Helicobacter pylori
  1094. HupA, the main undecaprenyl pyrophosphate and phosphatidylglycerol phosphate phosphatase in Helicobacter pylori is essential for colonization of the stomach
  1095. Interleukin‐27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori‐associated gastroduodenal diseases
  1096. The Cyclopropane Fatty Acid Synthase Mediates Antibiotic Resistance and Gastric Colonization of Helicobacter pylori
  1097. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
  1098. Helicobacter pylori Uses the TlpB Receptor To Sense Sites of Gastric Injury
  1099. Correction to: Mutations in the nucleotide binding and hydrolysis domains of Helicobacter pylori MutS2 lead to altered biochemical activities and inactivation of its in vivo function
  1100. Helicobacter pylori and low‐dose aspirin ulcer risk: A meta‐analysis
  1101. Serologic Response to Helicobacter pylori Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States
  1102. Gastric Cancer Prevention Using Helicobacter pylori Eradication in Japan
  1103. Genetic Determinants and Prediction of Antibiotic Resistance Phenotypes in Helicobacter pylori
  1104. Anti-Helicobacter pylori activity of ethoxzolamide
  1105. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp‐EuReg)
  1106. Potential Role of Biofilm Formation in the Development of Digestive Tract Cancer With Special Reference to Helicobacter pylori Infection
  1107. Acute and chronic gastritis due to Helicobacter pylori
  1108. Helicobacter pylori: Survival in cultivable and non-cultivable form in artificially contaminated Mytilus galloprovincialis
  1109. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
  1110. Gastric Helicobacter pylori infection perturbs human oral microbiota
  1111. Is there a difference concerning red cell distribution width in patient with or without Helicobacter pylori and gastric inflammation severity?
  1112. Molecular Links Between Alzheimer’s Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement
  1113. Asymptomatic Helicobacter pylori Infection in Preschool Children and Young Women Does Not Predict Iron Bioavailability from Iron-Fortified Foods
  1114. Synergistic effect of anti-Helicobacter pylori urease immunoglobulin Y from egg yolk of immunized hens and Lactobacillus johnsonii No.1088 to inhibit the growth of Helicobacter pylori in vitro and in vivo
  1115. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first‐line treatment of Helicobacter pylori infection: Two pilot studies
  1116. Interaction Between Ethnicity and Helicobacter pylori Infection in the Occurrence of Reflux Disease.
  1117. Characterization of spirugenic iron oxide nanoparticles and their antibacterial activity against multidrug-resistantHelicobacter pylori
  1118. Helicobacter pylori infection, atrophic gastritis, and risk of pancreatic cancer: A population-based cohort study in a large Japanese population: the JPHC Study
  1119. Helicobacter pylori Infection in Children and Adolescents
  1120. The Hippo Kinase LATS2 Controls Helicobacter pylori–Induced Epithelial–Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa
  1121. Identification of regulatory genes through global gene expression analysis of a Helicobacter pylori co-culture system
  1122. Inflammation, Immunity, and Vaccine Development for the Gastric Pathogen Helicobacter pylori
  1123. The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders
  1124. Helicobacter pylori infection selectively increases the risk for carotid atherosclerosis in young males
  1125. IDDF2019-ABS-0213 Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication- a multicentre randomised trial
  1126. Smoking andHelicobacter pyloriinfection: an individualparticipant pooled analysis (Stomach Cancer Pooling- StoPProject)
  1127. The Epidemiology of Gastric Cancers in the Era of Helicobacter pylori Eradication: A Nationwide Cancer Registry-Based Study in Taiwan
  1128. Helicobacter pylori infection and demyelinating disease of the central nervous system
  1129. Carcinogenic Helicobacter pylori Strains Selectively Dysregulate the In Vivo Gastric Proteome, Which May Be Associated with Stomach Cancer Progression
  1130. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?
  1131. Changes of Dyspeptic Symptom after Successful Eradication in Helicobacter pylori-Associated Dyspepsia
  1132. Increased risk of chronic myeloid leukaemia following gastric conditions indicating Helicobacter pylori infection: a case-control study
  1133. Chapter 33 – A Future for a Vaccine Against the Cancer-Inducing Bacterium Helicobacter pylori?
  1134. Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial
  1135. Are Patients with Perforated Peptic Ulcers Who are Negative for Helicobacter pylori at a Greater Risk?
  1136. Helicobacter pylori infection and peptic ulcers
  1137. Intraluminal therapy for Helicobacter pylori infection
  1138. Enhanced infectivity of strains of Helicobacter pylori isolated from children compared with parental strains
  1139. Pistacia vera L. oleoresin and levofloxacin is a synergistic combination against resistant Helicobacter pylori strains
  1140. Role of Helicobacter pylori in Upper Gastrointestinal Bleeding Among Ischemic Stroke Hospitalizations: A Nationwide Study of Outcomes
  1141. Sex differences in the prevalence of Helicobacter pylori infection
  1142. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis
  1143. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia
  1144. Characterization of a novel Helicobacter pylori East Asian-type CagA ELISA for detecting patients infected with various cagA genotypes
  1145. Impact of Helicobacter pylori Virulence Factors on the Host Immune Response and Gastric Pathology
  1146. T Cell–Dependent Maturation of Pathogen-Specific Igs in the Antrum of Chronically Helicobacter pylori–Infected Patients
  1147. Gastric Microbiota in Helicobacter pylori-Negative and -Positive Gastritis Among High Incidence of Gastric Cancer Area
  1148. The relationship between previous antimicrobial use, antimicrobial resistance and treatment outcome among Alaskans treated for Helicobacter pylori infection
  1149. In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori
  1150. Antibacterial activity of ovatodiolide isolated from Anisomeles indica against Helicobacter pylori
  1151. Urine testing and Helicobacter pylori infection
  1152. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin
  1153. Role of the protein CagA from Helicobacter pylori in the modifications of the human B lymphocyte cytoskeleton
  1154. Correction to: Mutations in the nucleotidebinding and hydrolysis domains ofHelicobacter pylori MutS2 lead to alteredbiochemical activities and inactivation of itsin vivo function
  1155. Tryptophan usage by Helicobacter pylori differs among strains
  1156. Carbohydrate-Dependent and Antimicrobial Peptide Defence Mechanisms Against Helicobacter pylori Infections
  1157. Detecting both current and prior Helicobacter pylori infection is important to assess its impact on dementia
  1158. Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota
  1159. Increase in antibiotic resistant Helicobacter pylori in a University Hospital in Japan
  1160. Reply to: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population
  1161. Helicobacter pylori Infection, the Gastric Microbiome and Gastric Cancer
  1162. Helicobacter pylori, stomach cancer and its prevention in New Zealand
  1163. Metronidazole for Helicobacter pylori eradication therapy among children and adolescents in Japan: Overcoming controversies and concerns
  1164. Helicobacter pylori Detection in Shellfish: A Real-Time Quantitative Polymerase Chain Reaction Approach
  1165. The Interaction of Helicobacter pylori with TFF1 and Its Role in Mediating the Tropism of the Bacteria Within the Stomach
  1166. Infections with Helicobacter pylori and challenges encountered in Africa
  1167. Influence of Living Environment during Childhood on Helicobacter pylori Infection in Japanese Young Adults
  1168. Is Helicobacter pylori associated with Behçet’s syndrome? A meta‐analysis
  1169. Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: A systematic review and meta-analysis
  1170. BetadefensinsandanalogsinHelicobacterpyloriinfections:mRNAexpressionlevels,DNAmethylation,andantibacterialactivity
  1171. Oral pH sensitive GNS@ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome
  1172. The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management
  1173. Clinical features of Helicobacter pylori antibody‐positive junior high school students in Nagano Prefecture, Japan
  1174. The frequency of Helicobacter pylori infection in patients with primary antibody deficiencies
  1175. Chronic Urticaria Associated withHelicobacter pylori
  1176. Immune Cell Signaling by Helicobacter pylori: Impact on Gastric Pathology
  1177. New insights into resistance of Helicobacter pylori against third‐ and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations
  1178. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials
  1179. Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study
  1180. Daphnetin: A Novel Anti-Helicobacter pylori Agent
  1181. Sequential Therapy for First-Line Helicobacter pylori Eradication: 10- or 14-Day Regimen?
  1182. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori
  1183. Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of Helicobacter pylori
  1184. Review: Epidemiology of Helicobacter pylori infection
  1185. Changes of tight junction and interleukin‐8 expression using a human gastroid monolayer model of Helicobacter pylori infection
  1186. The fragility of randomized trial outcomes underlying management of dyspepsia and Helicobacter pylori infections
  1187. Helicobacter pylori Infection and the Risk of Mortality in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Real-World Evidence Study
  1188. Evaluation of the epidemiological efficacy of eradicating Helicobacter pylori on development of gastric cancer
  1189. Association between atrial fibrillation and Helicobacter pylori
  1190. Efficacy of N-acetyl Cysteine in Patients with Dyspepsia with Negative Helicobacter pylori Infection
  1191. Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori–Infected CAPZA1-Overexpressing Cells
  1192. RIFABUTIN-BASED COMPOSITIONS AND METHODS FOR TREATING Helicobacter pylori INFECTION
  1193. Helicobacter pylori Antibody Titers in the High Normal Range Include Cases of H. pylori Infection in Patients with H. pylori-related Gastritis
  1194. Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two decades
  1195. Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia
  1196. Potential involvement of Helicobacter pylori from oral specimens in overweight body-mass index
  1197. Association between Helicobacter pylori infection, eradication and diabetes mellitus
  1198. Rapidly decreasing prevalence of Helicobacter pylori among Japanese children and adolescents
  1199. Lipopolysaccharides From Non-Helicobacter pylori Gastric Bacteria Potently Stimulate Interleukin-8 Production in Gastric Epithelial Cells
  1200. An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses
  1201. Helicobacter pylori growth stimulation by adrenaline detected by two methods
  1202. Review: Helicobacter pylori and non‐malignant upper gastrointestinal diseases
  1203. Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling
  1204. Helicobacter pylori Virulent Genes in the Upregulation of CCL20 and β-actin Expression and Progression towards Gastric Disorders
  1205. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm
  1206. Bone of Contention: Helicobacter pylori and Osteoporosis—Is There an Association?
  1207. Is there an association between Helicobacter pylori infection and irritable bowel syndrome? A meta-analysis
  1208. Abstract 1041: Casein kinase 2 modulates epithelial mesenchymal transition through Helicobacter pylori CagA dependent pathway in gastric cancer cells
  1209. Clostridiumdifficile‐associated disease and Helicobacter pylori seroprevalence: A case‐control study
  1210. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis
  1211. Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low‐resource Central America setting
  1212. Helicobacter pylori Seropositivity: Prevalence, Associations, and the Impact on Incident Metabolic Diseases/Risk Factors in the Population-Based KORA Study
  1213. Smoking, Helicobacter pylori Serology, and Gastric Cancer Risk in Prospective Studies from China, Japan, and Korea
  1214. Favorable outcomes of culture‐based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance
  1215. Immunity and Vaccine Development Against Helicobacter pylori
  1216. Role of sortase A in Lactobacillus gasseri Kx110A1 adhesion to gastric epithelial cells and competitive exclusion of Helicobacter pylori
  1217. oipA “on” status of Helicobacter pylori is associated with gastric cancer in North-Eastern Brazil
  1218. Development and Assessment of a Helicobacter pylori Medication Adherence and Stomach Cancer Prevention Curriculum for a Chinese American Immigrant Population
  1219. Unveiling the potentials of biocompatible silver nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori
  1220. Efficacy of Vonoprazan for Helicobacter pylori Eradication
  1221. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
  1222. Role of abnormal microRNA expression in Helicobacter pylori associated gastric cancer
  1223. Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection
  1224. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide cohort study
  1225. Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
  1226. Correlating prophage presence in Helicobacter pylori with restriction-modification systems
  1227. Chronic Urticaria Associated with Helicobacter pylori
  1228. Serum Pepsinogen Values in Japanese Junior High School Students With Reference to Helicobacter pylori Infection
  1229. Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
  1230. Effect of Helicobacter pylori biofilm formation on susceptibility to amoxicillin, metronidazole and clarithromycin
  1231. A liposomal drug delivery system for improved eradication of Helicobacter pylori
  1232. Circulating microRNA signatures serve as potential diagnostic biomarkers for Helicobacter pylori infection
  1233. Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success.
  1234. Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage
  1235. Correlation among fecal indicator bacteria and physicochemical parameters with the presence of Helicobacter pylori DNA in raw and drinking water from Bogotá, Colombia
  1236. The unique trimeric assembly of the virulence factor HtrA from Helicobacter pylori occurs via N-terminal domain swapping
  1237. In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori
  1238. Inactivation of NikR from Helicobacter pylori by a bismuth drug
  1239. Association of host immunity with Helicobacter pylori infection in recurrent gastric cancer
  1240. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing
  1241. Different phenotypes of gastric fundic gland polyposis and cancer in patients with familial adenomatous polyposis depending on Helicobacter pylori infection
  1242. Genome-wide mutation analysis of Helicobacter pylori after inoculation to Mongolian gerbils
  1243. Low-Molecular-Weight Dextran Sulfate Nanocapsules Inhibit the Adhesion of Helicobacter pylori to Gastric Cells
  1244. Application of convolutional neural networks for evaluating Helicobacter pylori infection status on the basis of endoscopic images
  1245. Recent trends in the prevalence of Helicobacter pylori in symptomatic children: A 12-year retrospective study in a tertiary centre
  1246. Helicobacter pylori infection is not associated with rheumatoid arthritis
  1247. Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment
  1248. High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial
  1249. Structure and Activity of PPX/GppA Homologs from Escherichia coli and Helicobacter pylori
  1250. Influence of Helicobacter pylori infection on periodontitis
  1251. Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome
  1252. Eradication of Helicobacter pylori Induces Immediate Regressive Changes in Early Gastric Adenocarcinomas
  1253. N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
  1254. Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Helicobacter pylori Infection
  1255. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 202
  1256. Modification of the Gastric Mucosal Microbiota by a Strain-Specific Helicobacter pylori Oncoprotein and Carcinogenic Histologic Phenotype
  1257. Effect of patchouli alcohol on Helicobacter pylori-induced neutrophil recruitment and activation
  1258. Tyrosine Kinases in Helicobacter pylori Infections and Gastric Cancer
  1259. Helicobacter pylori infection and risk of salmonella infection
  1260. A time‐saving–modified Giemsa stain is a better diagnostic method of Helicobacter pylori infection compared with the rapid urease test
  1261. The Role of E-cadherin in Helicobacter pylori-Related Gastric Diseases
  1262. Exosomal CagA derived from Helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis
  1263. Efficacy of N-acetyl Cysteine in Patients with Dyspepsia with Negative Helicobacter pyloriInfection
  1264. Current and Future Treatment of Helicobacter pylori Infections
  1265. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
  1266. Synthesis and In Vitro Enzymatic Studies of New 3-Aryldiazenyl Indoles as Promising Helicobacter pylori IMPDH Inhibitors
  1267. Atractylodes lancea volatile oils attenuated Helicobacter pylori NCTC11637 growth and biofilm
  1268. Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis
  1269. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
  1270. Helicobacter pylori pediatric infection changes FcεRI expression in dendritic cells and Treg profile in vivo and in vitro
  1271. Synthetic Lipopeptide Enhances Protective Immunity Against Helicobacter pylori Infection
  1272. Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori
  1273. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes
  1274. Clinical edge: The changing landscape of Helicobacter pylori – an update on diagnosis and treatment
  1275. Helicobacter pylori–induced matrix metallopeptidase-10 promotes gastric bacterial colonization and gastritis
  1276. β-carotene Inhibits Expression of c-Myc and Cyclin E in Helicobacter pylori-infected Gastric Epithelial Cells
  1277. Integration of virtual screening and susceptibility test to discover active-site subpocket-specific biogenic inhibitors of Helicobacter pylori shikimate dehydrogenase
  1278. Helicobacter pylori Infection and the Development of Advanced Colorectal Neoplasia.
  1279. A novel method for rapid detection of a Helicobacter pylori infection using a γ-glutamyltranspeptidase-activatable fluorescent probe
  1280. Helicobacter pylori infection and gastric cancer in the past, current and future in Europe.
  1281. Immune thrombocytopenia associated with Helicobacter pylori – unclear associative mechanisms
  1282. Deregulation of miRNA in Helicobacter pylori-Induced Gastric MALT Lymphoma: From Mice to Human
  1283. Distinct cytoskeletal proteins define zones of enhanced cell wall synthesis in Helicobacter pylori
  1284. Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA
  1285. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population
  1286. Review of antimicrobial peptides with anti‐Helicobacter pylori activity
  1287. MEK Inhibitor Reverses Metaplasia and Allows Re-Emergence of Normal Lineages in Helicobacter pylori–Infected Gerbils
  1288. Helicobacter pylori PROTEOME: THE STATE OF THE ART
  1289. Infections with Helicobacter pylori and challenges encountered in Africa
  1290. Influence of Living Environment during Childhood on Helicobacter pylori Infection in Japanese Young Adults
  1291. Is Helicobacter pylori associated with Behçet’s syndrome? A meta‐analysis
  1292. Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: A systematic review and meta-analysis
  1293. Beta-defensins and analogs in Helicobacter pylori infections: mRNA expression levels, DNA methylation, and antibacterial activity
  1294. Oral pH sensitive GNS@ ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome
  1295. The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management.
  1296. Clinical features of Helicobacter pylori antibody‐positive junior high school students in Nagano Prefecture, Japan
  1297. The frequency of Helicobacter pylori infection in patients with primary antibody deficiencies
  1298. Chronic Urticaria Associated with Helicobacter pylori
  1299. Immune Cell Signaling by Helicobacter pylori: Impact on Gastric Pathology
  1300. New insights into resistance of Helicobacter pylori against third‐ and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations
  1301. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials
  1302. Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study
  1303. Daphnetin: A Novel Anti-Helicobacter pylori Agent
  1304. Sequential therapy for first-line Helicobacter pylori eradication: 10-or 14-day regimen?
  1305. Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori
  1306. Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of Helicobacter pylori
  1307. Epidemiology of Helicobacter pylori infection
  1308. Changes of tight junction and interleukin‐8 expression using a human gastroid monolayer model of Helicobacter pylori infection
  1309. The fragility of randomized trial outcomes underlying management of dyspepsia and Helicobacter pylori infections
  1310. Helicobacter pylori Infection and the Risk of Mortality in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Real-World Evidence Study
  1311. Evaluation of the epidemiological efficacy of eradicating Helicobacter pylori on development of gastric cancer
  1312. Association between atrial fibrillation and Helicobacter pylori
  1313. Efficacy of N-acetyl Cysteine in Patients with Dyspepsia with Negative Helicobacter pylori Infection
  1314. Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori–Infected CAPZA1-Overexpressing Cells
  1315. RIFABUTIN-BASED COMPOSITIONS AND METHODS FOR TREATING Helicobacter pylori INFECTION
  1316. Helicobacter pylori Antibody Titers in the High Normal Range Include Cases of H. pylori Infection in Patients with H. pylori-related Gastritis
  1317. Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two …
  1318. Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia
  1319. Potential involvement of Helicobacter pylori from oral specimens in overweight body-mass index
  1320. Association between Helicobacter pylori infection, eradication and diabetes mellitus
  1321. Rapidly decreasing prevalence of Helicobacter pylori among Japanese children and adolescents
  1322. Lipopolysaccharides From Non-Helicobacter pylori Gastric Bacteria Potently Stimulate Interleukin-8 Production in Gastric Epithelial Cells
  1323. An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R-and IL-17R-dependent Th1 responses
  1324. Helicobacter pylori growth stimulation by adrenaline detected by two methods
  1325. Helicobacter pylori and non‐malignant upper gastrointestinal diseases
  1326. Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling
  1327. Helicobacter pylori Virulent Genes in the Upregulation of CCL20 and β-actin Expression and Progression towards Gastric Disorders
  1328. Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm
  1329. Bone of Contention: Helicobacter pylori and Osteoporosis—Is There an Association?
  1330. Is there an association between Helicobacter pylori infection and irritable bowel syndrome? A meta-analysis
  1331. Casein kinase 2 modulates epithelial mesenchymal transition through Helicobacter pylori CagA dependent pathway in gastric cancer cells
  1332. Clostridium difficile‐associated disease and Helicobacter pylori seroprevalence: A case‐control study
  1333. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis
  1334. Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low‐resource Central America setting
  1335. Helicobacter pylori seropositivity: Prevalence, associations and the impact on incident metabolic diseases/risk factors in the population-based KORA study
  1336. Smoking, Helicobacter pylori serology, and gastric cancer risk in prospective studies from China, Japan, and Korea
  1337. Favorable outcomes of culture‐based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance
  1338. Immunity and Vaccine Development Against Helicobacter pylori
  1339. Role of sortase A in Lactobacillus gasseri Kx110A1 adhesion to gastric epithelial cells and competitive exclusion of Helicobacter pylori
  1340. oip A “on” status of Helicobacter pylori is associated with gastric cancer in North-Eastern Brazil
  1341. Development and Assessment of a Helicobacter pylori Medication Adherence and Stomach Cancer Prevention Curriculum for a Chinese American Immigrant …
  1342. Unveiling the potentials of biocompatible silver nanoparticles on human lung carcinoma A549 cells and Helicobacter pylori
  1343. Efficacy of Vonoprazan for Helicobacter pylori Eradication
  1344. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
  1345. Role of abnormal microRNA expression in Helicobacter pylori associated gastric cancer
  1346. Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection
  1347. … temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori: a territory-wide …
  1348. Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
  1349. Correlating prophage presence in Helicobacter pylori with restriction-modification systems
  1350. Chronic Urticaria Associated with Helicobacter pylori
  1351. Serum Pepsinogen Values in Japanese Junior High School Students With Reference to Helicobacter pylori Infection
  1352. Novel insights of lymphomagenesis of Helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma
  1353. Effect of Helicobacter pylori biofilm formation on susceptibility to amoxicillin, metronidazole and clarithromycin
  1354. A liposomal drug delivery system for improved eradication of Helicobacter pylori
  1355. Circulating microRNA signatures serve as potential diagnostic biomarkers for Helicobacter pylori infection
  1356. Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success.
  1357. Helicobacter pylori eradication for metachronous gastric cancer: An unsuitable methodology impeding broader clinical usage
  1358. Correlation among fecal indicator bacteria and physicochemical parameters with the presence of Helicobacter pylori DNA in raw and drinking water from Bogotá …
  1359. The unique trimeric assembly of the virulence factor HtrA from Helicobacter pylori occurs via N-terminal domain swapping
  1360. In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori
  1361. Inactivation of NikR from Helicobacter pylori by a bismuth drug
  1362. Association of host immunity with Helicobacter pylori infection in recurrent gastric cancer
  1363. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing
  1364. Different phenotypes of gastric fundic gland polyposis and cancer in patients with familial adenomatous polyposis depending on Helicobacter pylori infection
  1365. Genome-wide mutation analysis of Helicobacter pylori after inoculation to Mongolian gerbils
  1366. Low-molecular-weight dextran sulfate nanocapsules inhibit the adhesion of Helicobacter pylori to gastric cells
  1367. Application of convolutional neural networks for evaluating Helicobacter pylori infection status on the basis of endoscopic images
  1368. The complete genome and methylome of Helicobacter pylori hpNEAfrica strain HP14039
  1369. Recent trends in the prevalence of Helicobacter pylori in symptomatic children: A 12-year retrospective study in a tertiary centre
  1370. Helicobacter pylori infection is not associated with rheumatoid arthritis
  1371. Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment
  1372. High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial
  1373. Structure and Activity of PPX/GppA Homologs from Escherichia coli and Helicobacter pylori
  1374. Influence of Helicobacter pylori infection on periodontitis
  1375. Helicobacter pylori Infection Does Not Impact on Lung Transplant Outcome
  1376. Eradication of Helicobacter pylori Induces Immediate Regressive Changes in Early Gastric Adenocarcinomas
  1377. N‐acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
  1378. Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Helicobacter pylori Infection
  1379. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020
  1380. Modification of the Gastric Mucosal Microbiota by a Strain-Specific Helicobacter pylori Oncoprotein and Carcinogenic Histologic Phenotype
  1381. Effect of patchouli alcohol on Helicobacter pylori-induced neutrophil recruitment and activation
  1382. Tyrosine Kinases in Helicobacter pylori Infections and Gastric Cancer
  1383. Helicobacter pylori infection and risk of salmonella infection
  1384. A time‐saving–modified Giemsa stain is a better diagnostic method of Helicobacter pylori infection compared with the rapid urease test
  1385. The Role of E-cadherin in Helicobacter pylori-Related Gastric Diseases
  1386. Exosomal CagA derived from Helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis
  1387. Efficacy of N-acetyl cysteine in dyspeptic patients with negative Helicobacter pylori infection
  1388. Current and Future Treatment of Helicobacter pylori Infections
  1389. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
  1390. Synthesis and in vitro enzymatic studies of new 3-aryldiazenyl indoles as promising Helicobacter pylori IMPDH inhibitors
  1391. Atractylodes lancea volatile oils attenuated Helicobacter pylori NCTC11637 growth and biofilm
  1392. Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity …
  1393. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
  1394. Helicobacter pylori pediatric infection changes FcεRI expression in dendritic cells and Treg profile in vivo and in vitro
  1395. Synthetic Lipopeptide Enhances Protective Immunity against Helicobacter pylori Infection
  1396. Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori
  1397. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes
  1398. Clinical edge: The changing landscape of Helicobacter pylori-an update on diagnosis and treatment
  1399. Helicobacter pylori–induced matrix metallopeptidase-10 promotes gastric bacterial colonization and gastritis
  1400. β-carotene Inhibits Expression of c-Myc and Cyclin E in Helicobacter pylori-infected Gastric Epithelial Cells
  1401. Integration of virtual screening and susceptibility test to discover active-site subpocket-specific biogenic inhibitors of Helicobacter pylori shikimate dehydrogenase
  1402. Helicobacter pylori Infection and the Development of Advanced Colorectal Neoplasia.
  1403. A novel method for rapid detection of a Helicobacter pylori infection using a γ-glutamyltranspeptidase-activatable fluorescent probe
  1404. Helicobacter pylori infection and gastric cancer in the past, current and future in Europe.
  1405. Immune thrombocytopenia associated with Helicobacter pylori-unclear associative mechanisms
  1406. Deregulation of miRNA in Helicobacter pylori-Induced Gastric MALT Lymphoma: From Mice to Human
  1407. Distinct cytoskeletal proteins define zones of enhanced cell wall synthesis in Helicobacter pylori
  1408. Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA
  1409. Eradication rate of Helicobacter pylori reinfection in Korea: A retrospective study
  1410. Selection of a fully human single domain antibody specific to Helicobacter pylori urease
  1411. Exploring the impact of Helicobacter pylori on gut microbiome composition
  1412. A Comment on Anti–Helicobacter pylori Therapy and Autoimmune Diseases
  1413. Thiamin transport in Helicobacter pylori lacking the de novo synthesis of thiamin
  1414. Relationship between Helicobacter pylori infection and gastric dysplasia: Results from histology of gastric samples in the South of Iran
  1415. Helicobacter pylori urease induces pro‐inflammatory effects and differentiation of human endothelial cells: Cellular and molecular mechanism
  1416. Noninvasive diagnostic tests for Helicobacter pylori infection
  1417. Colon Cancer Risk and VacA Toxin of Helicobacter pylori
  1418. Rapidly declining trend of signet ring cell cancer of the stomach may parallel the infection rate of Helicobacter pylori
  1419. Helicobacter pylori Infection and Vitamin B12 Deficiency During Early Pregnancy in an Urban Slum in Bangladesh (P24-035-19)
  1420. In vitro and In vivo Inhibition of Helicobacter pylori by Ethanolic Extracts of Lions Mane Medicinal Mushroom Hericium erinaceus (Agaricomycetes)
  1421. Association of active Helicobacter pylori infection and anemia in elderly males
  1422. IDDF2019-ABS-0144 Efficacy of 7-day vonoprazan and amoxicillin dual therapy as first-line Helicobacter pylori treatment: protocol of multi-center, non-inferiority …
  1423. The cost effectiveness of Helicobacter pylori population screening—economic evaluation alongside a randomised controlled trial with 13‐year follow‐up
  1424. Identification of selective inhibitors of Helicobacter pylori IMPDH as a targeted therapy for the infection
  1425. Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center
  1426. CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection
  1427. Recurrence of Helicobacter pylori infection: incidence and influential factors
  1428. Helicobacter pylori biofilm cells are metabolically distinct, express flagella, and antibiotic tolerant
  1429. PTU-066 Management of Helicobacter pylori infection in patients with upper GI bleeding: compliance with guidelines
  1430. Lifestyle Factors Rather Than Helicobacter pylori Infection or Estradiol Level are Associated With Osteopenia in Japanese Men
  1431. Study of rdxA and frxA genes mutations in metronidazole-resistant and-susceptible Helicobacter pylori clinical isolates from the central region of Portugal
  1432. Synthesis, Molecular Modelling and antibacterial activity against Helicobacter pylori of novel diflunisal derivatives as urease enzyme inhibitors
  1433. Helicobacter pylori Growth Stage Determines the Size, Protein Composition, and Preferential Cargo Packaging of Outer Membrane Vesicles
  1434. Structural Aspects of Helicobacter pylori Antibiotic Resistance
  1435. Helicobacter pylori infection: association with dietary habits and socioeconomic conditions
  1436. Evolutionary mechanism leading to the multi-cagA genotype in Helicobacter pylori
  1437. Fragment-based screening identifies inhibitors of ATPase activity and of hexamer formation of Cagα from the Helicobacter pylori type IV secretion system
  1438. DNA methylation accumulation in gastric mucosa adjacent to cancer after Helicobacter pylori eradication
  1439. Empiric Versus Resistance-Guided Therapy in Obese Patients with Helicobacter pylori Infection
  1440. Virulence factor genotyping of Helicobacter pylori isolated from Costa Rican dyspeptic patients
  1441. Epitope peptides of Helicobacter pylori CagA antibodies from sera by whole-peptide mapping
  1442. Potential of automatic diagnosis system with linked color imaging for diagnosis of Helicobacter pylori infection
  1443. Evaluation of a Novel Stool Antigen Rapid Test Kit for Detection of Helicobacter pylori Infection
  1444. Astaxanthin from Shrimp Cephalothorax Stimulates the Immune Response by Enhancing IFN-γ, IL-10, and IL-2 Secretion in Splenocytes of Helicobacter pylori
  1445. Prevalence of Helicobacter pylori infection and its associated diseases in low socio-economic workers in tertiary care hospital of Lahore, Pakistan
  1446. Helicobacter pylori Detected in Tap Water of Peruvian Patients with Gastric Cancer
  1447. Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradiation therapy
  1448. Accurate detection of Helicobacter pylori antigen in human stool specimens by two novel immunoassays
  1449. Tailor-Made Detection of Individual Phosphorylated and Non-Phosphorylated EPIYA-Motifs of Helicobacter pylori Oncoprotein CagA
  1450. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection
  1451. Oral administration of recombinant Bacillus subtilis spores expressing Helicobacter pylori neutrophil‐activating protein suppresses peanut allergy via up‐regulation …
  1452. Helicobacter pylori: a perspective in low- and middle-income countries
  1453. Long-term proton pump inhibitor use after Helicobacter pylori eradication may create a gastric environment for N-nitrosamine formation and gastric cancer …
  1454. Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial
  1455. Is breath testing without 13C-labelled external urea able to detect Helicobacter pylori infection?
  1456. Sugar-Modified Analogs of Auranofin Are Potent Inhibitors of the Gastric Pathogen Helicobacter pylori
  1457. Application of Helicobacter pylori stool antigen test to survey the updated prevalence of H. pylori infection in Taiwan
  1458. Correction: Kinetic and catalytic properties of M. HpyAXVII, a phase-variable DNA methyltransferase from Helicobacter pylori.
  1459. Prevalence of Helicobacter pylori cagA and sabA Genotypes in Patients with Gastric Disease
  1460. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness
  1461. An Updated Approach to Evaluation and Treatment of Helicobacter pylori Infection.
  1462. Helicobacter pylori: Infection and New Perspective for the Treatment
  1463. The Helicobacter pylori Urease Virulence Factor Is Required for the Induction of Hypoxia-Induced Factor-1α in Gastric Cells
  1464. ceRNA network construction and comparison of gastric cancer with or without Helicobacter pylori infection
  1465. Comparative study between Helicobacter pylori and host human genetics in the Dominican Republic
  1466. Anti-inflammatory effects of Kaempferol on Helicobacter pylori-induced inflammation
  1467. Reply to: Influence of Helicobacter pylori‐connected metabolic syndrome on non‐alcoholic fatty liver disease and its related colorectal neoplasm high risk
  1468. Back Cover: Helicobacter pylori Growth Stage Determines the Size, Protein Composition, and Preferential Cargo Packaging of Outer Membrane Vesicles
  1469. The validity of breath collection bags method in detecting Helicobacter pylori using the novel BreathID®Hp Lab System: a multicenter clinical study in 257 subjects
  1470. Association between Helicobacter pylori infection and arterial stiffness: Results from a large cross-sectional study
  1471. Randomized trial of vonoprazan‐based versus proton‐pump inhibitor‐based third‐line triple therapy with sitafloxacin for Helicobacter pylori
  1472. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018
  1473. Multidrug resistance in Helicobacter pylori: current state and future directions
  1474. Vitamin D3 activates the autolysosomal degradation function against Helicobacter pylori through the PDIA3 receptor in gastric epithelial cells
  1475. Molecular links between Alzheimer’s disease and Gastrointestinal microbiota with its-related metabolic syndrome: emphasis on Helicobacter pylori infection …
  1476. Search for potential Inducible Nitric Oxide Synthase inhibitors with favorable ADMET profiles for the therapy of Helicobacter pylori infections.
  1477. Kinetic and catalytic properties of M. HpyAXVII, a phase-variable DNA methyltransferase from Helicobacter pylori
  1478. Efficacy and safety of eradication therapy for elderly patients with Helicobacter pylori infection
  1479. GastroPanel® Biomarker Assay: The Most Comprehensive Test for Helicobacter pylori Infection and Its Clinical Sequelae. A Critical Review
  1480. VacA promotes CagA accumulation in gastric epithelial cells during Helicobacter pylori infection
  1481. Helicobacter pylori recrudescence and its influencing factors
  1482. Management of Helicobacter pylori in patients with immune thrombocytopenia
  1483. Potential of Helicobacter pylori‐uninfected signet ring cell carcinoma to invade the submucosal layer
  1484. Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions
  1485. Diabetes Increases Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study With Propensity Score Analysis
  1486. Helicobacter pylori seroprevalence in Spain: influence of adult and childhood sociodemographic factors
  1487. Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen?
  1488. 1071PDTreatment outcome for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma
  1489. Helicobacter pylori infection, serum pepsinogens as markers of atrophic gastritis, and leukocyte telomere length: a population-based study
  1490. Characterization and Antibacterial Activity Against Helicobacter pylori of Lactic Acid Bacteria Isolated from Thai Fermented Rice Noodle
  1491. Banxia Xiexin Decoction for patients with peptic ulcer or chronic gastritis infected with Helicobacter pylori
  1492. Mixed Borrelia burgdorferi and Helicobacter pylori Biofilms in Morgellons Disease Dermatological Specimens
  1493. … PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized …
  1494. Helicobacter pylori Infection Prevalence and Histopathologic Findings in Laparoscopic Sleeve Gastrectomy
  1495. Molecular evolution of the VacA p55 binding domain of Helicobacter pylori in mestizos from a high gastric cancer region of Colombia
  1496. Correction: Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of: Helicobacter pylori
  1497. Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center …
  1498. Downregulation of miR‐146a promotes cell migration in Helicobacter pylori–negative gastric cancer
  1499. Gastric Parietal Cell Physiology and Helicobacter pylori-Induced Disease
  1500. Antimicrobial effects of black rice extract on Helicobacter pylori infection in Mongolian gerbil
  1501. Association of Clinicopathological features of Cholecystitis with Helicobacter pylori Infection in Gall bladders
  1502. Helicobacter pylori-induced DNA methylation as an epigenetic modulator of gastric cancer: recent outcomes and future direction
  1503. Is Human Papillomavirus and Helicobacter pylori Related in Gastric Lesions?
  1504. Anti-urease immunoglobulin (IgY) from egg yolk prevents Helicobacter pylori infection in a mouse model
  1505. … -0126 Levofloxacin sequential therapy versus bismuth quadruple therapy in the second-line and third-line treatment of Helicobacter pylori-a multicenter randomized …
  1506. Relationship between Helicobacter pylori infection and obesity in Chinese adults: A systematic review with meta-analysis
  1507. Helicobacter pylori VacA, a distinct toxin exerts diverse functionalities in numerous cells: An overview
  1508. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy
  1509. Exploring the synthetic application of Helicobacter pylori α1, 3/4-fucosyltransferase FucTIII toward the syntheses of fucosylated human milk glycans and Lewis …
  1510. Western-Type Helicobacter pylori CagA are the Most Frequent Type in Mongolian Patients
  1511. Biopolymers-based gastroretentive buoyant systems for therapeutic management of Helicobacter pylori infection
  1512. Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer: a systematic review and meta-analysis
  1513. Gastric Tumorigenesis: Role of Inflammation and Helicobacter pylori
  1514. Influence of serum vitamin D level on Helicobacter pylori eradication: a multi‐center, observational, prospective and cohort study
  1515. Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism
  1516. Neutralizing antibodies for Helicobacter pylori urease inhibit bacterial colonization in the murine stomach in vivo
  1517. Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic
  1518. Analysis of core protein clusters identifies candidate variable sites conferring metronidazole resistance in Helicobacter pylori
  1519. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication
  1520. Correlation between macrophage migration inhibitory factor and autophagy in Helicobacter pylori-associated gastric carcinogenesis
  1521. Association of TLR4 Polymorphisms, Expression, and Vitamin D with Helicobacter pylori Infection
  1522. Downregulation of tumor suppressor RACK1 by Helicobacter pylori infection promotes gastric carcinogenesis through the integrin β-1/NF-κB signaling pathway
  1523. Are probiotics useful for therapy of Helicobacter pylori diseases?
  1524. Helicobacter pylori infection and the risk of colorectal cancer: a nationwide population-based cohort study
  1525. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study
  1526. Lower Risk of Gastric Atrophy and Intestinal Metaplasia in Patients with MALT Lymphoma despite Helicobacter pylori Infection
  1527. A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report
  1528. IDDF2019-ABS-0317 Incidence of Helicobacter pylori antibiotic resistance a single center cross-sectional study
  1529. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition
  1530. Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia
  1531. Planning Mass Eradication of Helicobacter pylori Infection for Indigenous Taiwanese Peoples to Reduce Gastric Cancer
  1532. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma.
  1533. Prevalence of Helicobacter pylori infection in Sari Northern Iran; a population based study
  1534. Gastric juice‐based PCR assay: An alternative testing method to aid in the management of previously treated Helicobacter pylori infection
  1535. Helicobacter pylori Colonisation in Heterotopic Gastric Mucosa in Meckel Diverticulum: Case Report and Review of the Literature
  1536. Reply To: A Comment on Helicobacter pylori and Lung Transplant Outcome: Is Serology the Ideal Diagnostic Approach?
  1537. Investigating effect of Helicobacter pylori treatment on improvement of non-alcoholic fatty liver parameters: a randomized trial
  1538. Complete genome sequence of Helicobacter pylori B128 7.13 and a single‐step method for the generation of unmarked mutations
  1539. Antimicrobial susceptibility and mutations in the 23S rRNA gen of Helicobacter pylori in dyspeptic patients
  1540. Influence of Helicobacter pylori Infection and Atrophic Gastritis on the Gut Microbiota in a Japanese Population
  1541. Gastric subserous vaccination with Helicobacter pylori vaccine: an attempt to establish tissue-resident CD4+ memory T cells and induce prolonged protection
  1542. The effect of Helicobacter pylori infection and different H. pylori components on the proliferation and apoptosis of gastric epithelial cells and fibroblasts
  1543. Eradication of Helicobacter pylori in Patients with Inflammatory Bowel Disease for Prevention of Recurrences-Impact on the Natural History of the Disease
  1544. Management of Helicobacter pylori infection by clinicians: A nationwide survey in a developing country
  1545. Impaired gastric mucosal integrity identified by confocal endomicroscopy in Helicobacter pylori‐negative functional dyspepsia
  1546. Prognostic significance of Helicobacter pylori-infection in gastric diffuse large B-cell lymphoma
  1547. Noninvasive Helicobacter pylori Diagnostic Methods in Indonesia.
  1548. Propolis polyphenolic compounds affect the viability and structure of Helicobacter pylori in vitro
  1549. Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton …
  1550. Helicobacter pylori and diabetes mellitus: a controversial relationship.
  1551. Association between atrial fibrillation and Helicobacter pylori
  1552. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
  1553. Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed
  1554. … -loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori
  1555. Influence of Helicobacter pylori‐connected metabolic syndrome on non‐alcoholic fatty liver disease and its related colorectal neoplasm high risk
  1556. … testing of nitroethylene-and 7-nitrobenzoxadiazol-based flavodoxin inhibitors against Helicobacter pylori drug-resistant clinical strains and in Helicobacter pylori
  1557. Autoantibodies to a specific peptide epitope of human Hsp60 (ATVLA) with homology to Helicobacter pylori HspB in H. pylori‐infected patients
  1558. 2165. Helicobacter pylori Infections in the Bronx, New York: Whole-Genome Sequencing for Rapid Genotypic Susceptibility Testing.
  1559. Helicobacter pylori infection alters gastric and tongue coating microbial communities
  1560. Role of Th22 cells in Helicobacter pylori-related gastritis and peptic ulcer diseases
  1561. Role of NOD1 and ALPK1/TIFA Signalling in Innate Immunity Against Helicobacter pylori Infection
  1562. Helicobacter pylori prevalence and risk factors among children with celiac disease.
  1563. Helicobacter pylori antimicrobial resistance during a 5‐year period (2013‐2017) in northern Spain and its relationship with the eradication therapies
  1564. Impact factors that modulate gastric cancer risk in Helicobacter pylori‐infected rodent models
  1565. Screening and characterization of nucleic acid aptamers specifically binding to adhesin HpaA from Helicobacter pylori
  1566. Association of Helicobacter pylori infection with metabolic syndrome in aged Chinese females
  1567. PTU-071 Helicobacter pylori brexit: NICE vs maastricht A comparison of eradication guidelines and resistance in London
  1568. Cost‐effectiveness analysis of screen‐and‐treat strategy in asymptomatic Chinese for preventing Helicobacter pylori‐associated diseases
  1569. Treatment for Helicobacter pylori appears to reduce the incidence of gastric cancer: eradication effect or screening effect?
  1570. Relationship between primary eradication of Helicobacter pylori and drinking habits in women: collaborative research between a pharmacy and a clinic
  1571. Prevalence of human papillomavirus and Helicobacter pylori in esophageal and gastroesophageal junction cancer biopsies from a case–control study in …
  1572. Depressed gastric-type adenoma in nonatrophic gastric mucosa without Helicobacter pylori infection
  1573. Helicobacter pylori‐downregulated tumor necrosis factor receptor‐associated protein 1 mediates apoptosis of human gastric epithelial cells
  1574. SIRT1-targeted miR-543 autophagy inhibition and epithelial–mesenchymal transition promotion in Helicobacter pylori CagA-associated gastric cancer
  1575. A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection
  1576. A167 ANTIMICROBIAL SUSCEPTIBILITY OF Helicobacter pylori IN THE SASKATOON HEALTH REGION
  1577. The relationship between Helicobacter pylori–related microbiota dysbiosis and gastrointestinal tract pathologies
  1578. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model
  1579. Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance
  1580. A Novel Role for Helicobacter pylori Gamma-Glutamyltranspeptidase in Regulating Autophagy and Bacterial Internalization in Human Gastric Cells
  1581. Burden of disease from Helicobacter pylori infection in western Canadian Arctic communities
  1582. Helicobacter pylori Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania
  1583. Long‐term effect of Helicobacter pylori eradication on prevalence of reflux esophagitis
  1584. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion
  1585. One piece biopsy for both rapid urease test and cultivation of Helicobacter pylori
  1586. Immunoinformatics approaches to explore Helicobacter pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine
  1587. Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line Helicobacter pylori eradication
  1588. Hierarchical-Clustering, Scaffold-Mining Exercises and Dynamics Simulations for Effectual Inhibitors Against Lipid-A Biosynthesis of Helicobacter pylori
  1589. Inhibitory Effects of Menadione on Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation via NF-κB Inhibition
  1590. Evolution of Helicobacter pylori associated with gastroduodenal ulcers or erosions in children over the past 23 years: Decline or steady state?
  1591. Comparison of Helicobacter pylori stool antigen, salivary IgG, serum IgG, and serum IgM as diagnostic markers of H. pylori infection in children
  1592. Teprenone for the prevention of low-dose aspirin-induced gastric mucosal injury in Helicobacter pylori-negative patients
  1593. Helicobacter pylori and its hematological effect
  1594. The mucosal adjuvant effect of plant polysaccharides for induction of protective immunity against Helicobacter pylori infection
  1595. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations
  1596. Differences in Helicobacter pylori and CagA antibody changes after eradication between subjects developing and not developing gastric cancer
  1597. Helicobacter pylori inhibits GKN1 expression via the CagA/p‐ERK/AUF1 pathway
  1598. Relationship between African Biogeographical Ancestry and Helicobacter pylori infection in children of a large Latin American urban center
  1599. Prevalence of clarithromycin-resistant Helicobacter pylori in children living in South of Sweden: a 12-year follow-up
  1600. Altered Mucin Expression in the Gastric Epithelium After Injury and Regeneration May Result in Increased Helicobacter pylori-Induced Gastric Ulcers in the Elderly
  1601. Effect of Helicobacter pylori Treatment on Unexplained Iron Deficiency Anemia
  1602. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus
  1603. Incidence of metachronous gastric cancer in patients whose primary gastric neoplasms were discovered after Helicobacter pylori eradication
  1604. Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori
  1605. In silico probing exercises, bioactive-conformational and dynamic simulations strategies for designing and promoting selective therapeutics against Helicobacter pylori
  1606. Helicobacter pylori eradication regimens in an antibiotic high‐resistance European area: A cost‐effectiveness analysis
  1607. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults
  1608. Benefit of Helicobacter pylori eradication therapy in all systemic sclerosis patients regardless of clinical symptoms.
  1609. A Next-Generation Sequencing-Based Approach to Identify Genetic Determinants of Antibiotic Resistance in Cambodian Helicobacter pylori Clinical Isolates
  1610. Identification of Anti-Helicobacter pylori Compounds From Usnea undulata
  1611. Helicobacter pylori and Related Diseases
  1612. Impact of nitric oxide’s bidirectional role on glaucoma: focus on Helicobacter pylori–related nitrosative stress
  1613. ENDOSCOPIC BIOPSY PROVEN CO-INFECTION OF Helicobacter pylori AND GIARDIA LAMBLIA IN ADULT POPULATION OF KARACHI CITY
  1614. Activation of CD3+ T cells by Helicobacter pylori DNA vaccines in potential immunotherapy of gastric carcinoma
  1615. Potential transmission sources of Helicobacter pylori infection: detection of H. pylori in various environmental samples
  1616. Helicobacter pylori upregulates TRPC6 via Wnt/β-catenin signaling to promote gastric cancer migration and invasion
  1617. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates
  1618. Previous Helicobacter pylori infection–induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication
  1619. Helicobacter pylori infections in Ethiopia; prevalence and associated factors: a systematic review and meta-analysis
  1620. Inverse association of Helicobacter pylori cagPAI genotypes with risk of cardia and non‐cardia gastric adenocarcinoma
  1621. Correlates of infection with Helicobacter pylori positive and negative cytotoxin-associated gene A phenotypes among Arab and Jewish residents of Jerusalem
  1622. Systematic review: Would susceptibility‐guided treatment achieve acceptable cure rates for second‐line Helicobacter pylori therapy as currently practiced?
  1623. Properties of the HtrA protease from bacterium Helicobacter pylori whose activity is indispensable for growth under stress conditions
  1624. Helicobacter pylori in allergic and non-allergic rhinitis does play a protective or causative role?
  1625. Influence of Helicobacter pylori Infection on Endoscopic Findings of Gastric Adenocarcinoma of the Fundic Gland Type
  1626. The Accuracy of the Serum Antibody Test for Helicobacter pylori Infection among Junior High School Students
  1627. In Silico and In Vitro Anti-Helicobacter pylori Effects of Combinations of Phytochemicals and Antibiotics
  1628. Mechanistic Insight into the Interaction between Helicobacter pylori Urease Subunit α and Its Molecular Chaperone Hsp60
  1629. Eradication therapy for Helicobacter pylori infection improves nutrition status in Japanese hemodialysis patients: a pilot study
  1630. Ulcer disease and Helicobacter pylori infection: current treatment
  1631. Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism …
  1632. Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag® H. pylori + ClariR assay
  1633. Spasmolytic polypeptide‐expressing metaplasia associated with higher expressions of miR‐21, 155, and 223 can be regressed by Helicobacter pylori eradication in …
  1634. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics
  1635. In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives
  1636. Characterisation of point mutations in domain V of the 23S rRNA gene of clinical Helicobacter pylori strains and clarithromycin-resistant phenotype in central Vietnam
  1637. Molecular Diagnosis of Helicobacter pylori Antibiotic Resistance in Taif Region, Saudi Arabia
  1638. Structural analysis of the flagellar capping protein FliD from Helicobacter pylori
  1639. up-regulation of Mir-1915 Inhibits Proliferation, Invasion, and Migration of Helicobacter pylori-Infected Gastric cancer cells via targeting rAGE
  1640. Interactions between Helicobacter pylori and gastroesophageal reflux disease
  1641. Histological Features of Gastric Mucosa Serologically Diagnosed as Gastric Atrophy without Helicobacter pylori Infection
  1642. Post Helicobacter pylori Gastric Diseases
  1643. Polysorbate 80 add-on therapy in the treatment of Helicobacter pylori infection: Polysorbate 80 and HP antibiotic resistance
  1644. Antimicrobial activities of peptide Cbf-K16 against drug-resistant Helicobacter pylori infection in vitro and in vivo
  1645. A lucid review of Helicobacter pylori‐induced DNA damage in gastric cancer
  1646. Characterization of vacuolating cytotoxin A of Helicobacter pylori in cell binding and cellular activity
  1647. Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy
  1648. Association between IL-1B gene polymorphisms and Helicobacter pylori infection: A meta-analysis
  1649. Rate and predictive factors of Helicobacter pylori recurrence: Analysis of a screening cohort
  1650. Combined Effect Of Helicobacter pylori Infection And Elevated C-Reactive Protein On 3-Month Prognosis Of Ischemic Stroke
  1651. Crystal structure of the flagellin protein FlaG from Helicobacter pylori
  1652. Polymorphism in Toll-Like Receptors and Helicobacter pylori Motility in Autoimmune Atrophic Gastritis and Gastric Cancer
  1653. Characteristics and Predictive Factor of Helicobacter pylori-Associated Functional Dyspepsia in Japanese Patients
  1654. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study
  1655. Evaluation of Clarithromycin and Metronidazole Resistance of Helicobacter pylori Infection in Symptomatic Iranian Children
  1656. The ‘missing’gastric microbe; the impact of gastric cancer-associated microbiota on Helicobacter pylori growth in vitro and its implications in gastric carcinogenesis
  1657. Insights into the Suppression of Multidrug-Resistant Helicobacter pylori by Probiotics Supernatant
  1658. Extraction of molecular features for the drug discovery targeting protein‐protein interaction of Helicobacter pylori CagA and tumor suppressor protein ASSP2
  1659. Evaluation of Four Different DNA Targets in Polymerase Chain Reaction for Detection and Genotyping of Helicobacter pylori
  1660. Association Between Seropositivity of Helicobacter pylori Infection and Anaemia Amongst Children Aged 5-15 Years in Western Highlands of Kenya
  1661. Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review
  1662. Relationship of Helicobacter pylori Infection with Gastric Black Spots Shown by Endoscopy
  1663. A combination of serum anti-Helicobacter pylori antibody titer and Kyoto classification score could provide a more accurate diagnosis of H pylori
  1664. Antibacterial activity of Na-clinoptilolite against Helicobacter pylori: in-vitro tests, synergistic effect with amoxicillin and stability of the antibiotic formulated with the …
  1665. STRUCTURAL AND FUNCTIONAL STUDIES ON THE Helicobacter pylori PROTEOME
  1666. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in …
  1667. 1081P Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
  1668. Development of a Berberine Loaded Multifunctional Design for the Treatment of Helicobacter pylori Induced Gastric Ulcer
  1669. Preventing Metachronous Gastric Cancer after the Endoscopic Resection of Gastric Epithelial Neoplasia: Roles of Helicobacter pylori Eradication and Aspirin
  1670. Epigenetic changes in gastric cancer induction by Helicobacter pylori
  1671. Demographics and Clinical and Endoscopic Characteristics of Patients with Helicobacter pylori Infection and Gastroesophageal Reflux Disease: A Case-Control Study
  1672. Pathogenesis and clinical management of Helicobacter pylori gastric infection
  1673. Assessment of prevalence and risk factors of Helicobacter pylori infection in an oilfield Community in Hebei, China
  1674. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients
  1675. Helicobacter pylori antibiotic sensitivity pattern in dyspeptic patients in Kano, Nigeria
  1676. Molecular interaction between human SUMO-I and histone like DNA binding protein of Helicobacter pylori (Hup) investigated by NMR and other biophysical tools
  1677. Helicobacter pylori inhibited cell proliferation in human periodontal ligament fibroblasts through the Cdc25C/CDK1/cyclinB1 signaling cascade
  1678. Online registry for nationwide database of Helicobacter pylori eradication in Korea: Correlation of antibiotic use density with eradication success
  1679. Prevalence and associated factors of Helicobacter pylori Infection among HIV positive adults onAnti-retroviral Therapy
  1680. Helicobacter pylori infection promotes epithelial-to-mesenchymal transition of gastric cells by upregulating LAPTM4B
  1681. Molecular association of FtsZ with the intrabacterial nanotransportation system for urease in Helicobacter pylori
  1682. Helicobacter pylori infection increases risk of incident metabolic syndrome and diabetes: A cohort study
  1683. Study of the Coexistence of Helicobacter pylori and Candida in the Saliva of Patients with Dyspepsia
  1684. Verrucous antral gastritis in relation to Helicobacter pylori infection, nutrition, and gastric atrophy
  1685. Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer
  1686. Single-nucleotide polymorphisms in Toll-like receptor genes are associated with the prognosis of gastric cancer and are not associated with Helicobacter pylori
  1687. Bismuth‐containing quadruple therapy versus concomitant quadruple therapy as first‐line treatment for Helicobacter pylori infection in an area of high resistance to …
  1688. Helicobacter pylori and nutrition: a bidirectional communication.
  1689. … IL-17RB expression impairs CD11b+ CD11c− myeloid cell accumulation in gastric mucosa and host defense during the early-phase of Helicobacter pylori
  1690. Effect of patchouli alcohol on macrophage mediated Helicobacter pylori digestion based on intracellular urease inhibition
  1691. 1500. Gastric Carcinoma Survival Related with Helicobacter pylori Infection in Cali, Colombia: A Hospital-Based Cancer Study.
  1692. Systematic review and meta‐analysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria
  1693. Helicobacter pylori (HP) infection alone, but not HP-induced atrophic gastritis, increases the risk of gastric lymphoma: a case-control study in Japan
  1694. Positive Association Between Helicobacter pylori Infection and Metabolic Syndrome in a Korean Population: A Multicenter Nationwide Study
  1695. Helicobacter pylori infection associated with an increased risk of colorectal adenomatous polyps in the Chinese population
  1696. Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance …
  1697. Prevalence of Helicobacter pylori Infection in Patients with Chronic Kidney Disease
  1698. Helicobacter pylori is associated with poor prognosis of laryngeal precancerous lesion
  1699. Helicobacter pylori infection aggravates dysbiosis of gut microbiome in children with gastritis
  1700. Immunization with a Synthetic Helicobacter pylori Peptide Induces Secretory IgA Antibodies and Protects Mice against Infection
  1701. How does Helicobacter pylori cause gastric cancer through connexins: An opinion review
  1702. Does Helicobacter pylori Eradication Reduce the Incidence of Metachronous Gastric Cancer After Curative Endoscopic Resection of Early Gastric Cancer: A …
  1703. Comparison of the detection of Helicobacter pylori infection by commercially available serological testing kits and the 13C-urea breath test
  1704. Impact of Helicobacter pylori Eradication in Children with Acute Immune Thrombocytopenia: A Randomized Controlled Study
  1705. A new anti-Helicobacter pylori juglone from Reynoutria japonica
  1706. Estimating the Force of Infection with Helicobacter pylori in Japan
  1707. Discovery and validation of methylated-differentially expressed genes in Helicobacter pylori-induced gastric cancer
  1708. Low-Molecular-Weight Dextran Sulfate Nanocapsules Inhibit the Adhesion of Helicobacter pylori to Gastric Cells
  1709. Is there any relationship between Helicobacter pylori infection and human epidermal growth factor receptor 2 expression in gastric cancer?
  1710. VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1
  1711. Gastric Mucosa Plasma Cells is Unspecific for Diagnosing Helicobacter pylori Infection
  1712. A Longitudinal, Population-Level, Big-Data Study of Helicobacter pylori-Related Disease across Western Australia
  1713. Cost‐effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin …
  1714. Helicobacter pylori infection as a risk factor for serum bilirubin change and less favourable lipid profiles: a hospital-based health examination survey
  1715. High Helicobacter pylori Bacterial Load and Low Cytokine Expression Levels Are Associated with Nodular Gastropathy
  1716. Amoxicillin-Clarithromycin-Containing Bismuth Quadruple Therapy for Primary Eradication of Helicobacter pylori
  1717. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1,200 patients
  1718. Helicobacter pylori and its antibiotic heteroresistance: A neglected issue in published guidelines
  1719. Evaluation of Helicobacter pylori Infection and Its Relation with Coated Tongue in Patients Referring to UBT
  1720. Effect of vitamin D on Helicobacter pylori infection and eradication: A meta‐analysis
  1721. The effect of synbiotics in improving Helicobacter pylori eradication: A systematic review and meta-analysis
  1722. Inhibitory Effects of β-caryophyllene on Helicobacter pylori Infection: A Randomized Double-blind, Placebo-controlled Study
  1723. Helicobacter pylori Ribosomal Protein-A2 Peptide/Silk Fibroin Nanofibrous Composites as Potential Wound Dressing
  1724. An association of Helicobacter pylori infection with endoscopic and histological findings in the Nepalese population
  1725. Changes in Helicobacter pylori Immunoglobulin G Levels and Gastric Mucosal Atrophy after Successful Eradication of Helicobacter pylori
  1726. Differential Helicobacter pylori Plasticity in the Gastric Niche of Subjects at Increased Gastric Cancer Risk
  1727. Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan
  1728. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis
  1729. Population-level macrolide consumption is associated with clarithromycin resistance in Helicobacter pylori: an ecological analysis
  1730. Successful Eradication of Helicobacter pylori Could Prevent Metachronous Gastric Cancer: A Propensity Matching Analysis
  1731. Protective effect of curcumin decreases incidence of gastric cancer induced by Helicobacter pylori and N-methyl-N-nitrosourea in rats
  1732. An overview of nanotechnology-based treatment approaches against Helicobacter pylori
  1733. Helicobacter pylori Infection following Endoscopic Resection of Early Gastric Cancer
  1734. Helicobacter pylori Infection and Psoriasis: A Systematic Review and Meta-Analysis
  1735. Synergistic effect of 2D material coated Pt nanoparticles with PEDOT polymer on electrode surface interface for a sensitive label free Helicobacter pylori CagA (Ag-Ab) …
  1736. Allicin as add-on therapy for Helicobacter pylori infection: A systematic review and meta-analysis
  1737. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients
  1738. A food-grade engineered Lactococcus lactis strain delivering Helicobacter pylori Lpp20 alleviates bacterial infection in H. pylori-challenged mice
  1739. α-Lipoic Acid Inhibits IL-8 Expression by Activating Nrf2 Signaling in Helicobacter pylori-infected Gastric Epithelial Cells
  1740. The role of Helicobacter pylori DnaA domain I in orisome assembly on a bipartite origin of chromosome replication
  1741. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis
  1742. Formulation and evaluation of bilayer tablets of clarithromycin and omeprazole against Helicobacter pylori infection
  1743. IDDF2019-ABS-0146 Efficacies of tailored therapy versus guideline-recommended empiricaltherapies for eradication of Helicobacter pylori–a trend survey over 20 …
  1744. DIAGNOSTIC OF Helicobacter pylori VIA ENDOSCOPY: THE CLINICAL ISSUE OF SUPPRESSIVE CONDITIONS
  1745. The Diagnosis and Therapy of Helicobacter pylori Infection in Hungary: Comparison of Strategies Applied by Family Physicians and Internists
  1746. Inflammatory responses induced by Helicobacter pylori on the carcinogenesis of gastric epithelial GES‑1 cells
  1747. T-bet+ Cells Polarization in Patients Infected with Helicobacter pylori Increase the Risk of Peptic Ulcer Development
  1748. Faster Detection of Helicobacter pylori Infection by 13 C-Urea Breath Test. Comparing Short versus Standard Sampling Time.
  1749. Relationship between Helicobacter pylori Infection and Plasmacytoid and Myeloid Dendritic Cells in Peripheral Blood and Gastric Mucosa of Children
  1750. Increased serum gastrin in patients with different clinical forms of Chagas disease coinfected with Helicobacter pylori
  1751. The Role of Host Genetic Polymorphisms in Helicobacter pylori Mediated Disease Outcome
  1752. Associations of a NLRP3 rs10754558 Polymorphism with Helicobacter pylori-Infected Patients with Gastritis and Peptic Ulcer Disease
  1753. Prediction of progression of chronic atrophic gastritis with Helicobacter pylori and poor prognosis of gastric cancer by CYP3A4
  1754. Helicobacter pylori vacA, cagA and iceA genotypes in dyspeptic patients from southwestern region, Saudi Arabia: distribution and association with clinical …
  1755. Development of a novel gene signature in patients without Helicobacter pylori infection gastric cancer
  1756. A novel taxon selection method, aimed at minimizing recombination, clarifies the discovery of a new sub‐population of Helicobacter pylori from Australia
  1757. Eradicating Helicobacter pylori Infections to Treat Ulcers: Case Histories of Significant Medical Advances
  1758. Upregulation of MUC5AC production and deposition of LEWIS determinants by Helicobacter pylori facilitate gastric tissue colonization and the …
  1759. Accuracies of Endoscopic Diagnosis of Helicobacter pylori-Gastritis: Multicenter Prospective Study Using White Light Imaging and Linked Color Imaging
  1760. Circulating CD14+ CD163+ CD209+ M2-like monocytes are associated with the severity of infection in Helicobacter pylori-positive patients
  1761. Expression of Circadian Clock Components PER2 and BMAL1 are Altered During Infection of Helicobacter pylori
  1762. Helicobacter pylori heteroresistance to clarithromycin in adults—New data by in situ detection and improved concept
  1763. Astaxanthin Prevents Decreases in Superoxide Dismutase 2 Level and Superoxide Dismutase Activity in Helicobacter pylori-infected Gastric Epithelial Cells
  1764. Accuracy of invasive and noninvasive methods of Helicobacter pylori infection diagnosis in Saudi children
  1765. The Role of C5-cytosine Methyltransferase, hpyAVIBM in Helicobacter pylori Associated Virulence in Mice
  1766. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A …
  1767. Vaccine‐induced gastric CD4+ tissue‐resident memory T cells proliferate in situ to amplify immune response against Helicobacter pylori insult
  1768. Role of Helicobacter pylori-induced Antralization in Gastric Carcinogenesis and its Implications in Clinical Practice
  1769. Periodontal treatment is more effective in gastric Helicobacter pylori eradication in those patients who maintain good oral hygiene
  1770. Syk: a new target for attenuation of Helicobacter pylori-induced gastric mucosal inflammatory responses
  1771. Lack of Association between Past Helicobacter pylori Infection and Diabetes: A Two-Cohort Study
  1772. Lactobacillus gasseri suppresses the production of the proinflammatory cytokines in Helicobacter pylori-infected macrophages by inhibiting the expression of ADAM17
  1773. Effectiveness and safety of furazolidone‐containing quadruple regimens in patients with Helicobacter pylori infection in real‐world practice
  1774. Differential diagnosis of Helicobacter pylori-associated gastritis with the linked-color imaging score
  1775. Ultrastructure Characteristics of Different Chinese Medicine Syndromes of Helicobacter pylori-Correlated Gastric Diseases
  1776. Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection
  1777. Treating Helicobacter pylori infection in the face of growing antibiotic resistance.
  1778. Asymmetric dimethylation and citrullination of proteinic arginine and homoarginine synthesis in human Helicobacter pylori infection
  1779. The analysis of virulence factors and antibiotic resistance between Helicobacter pylori strains isolated from gastric antrum and body
  1780. Association of p53 Gene Mutation With Helicobacter pylori Infection in Gastric Cancer Patients and Its Correlation With Clinicopathological and Environmental …
  1781. Helicobacter pylori Infection and Glaucoma
  1782. Risks of substance uses, alcohol flush response, Helicobacter pylori infection and upper digestive tract diseases—An endoscopy cross‐sectional study
  1783. Eradication of Helicobacter pylori in a Living Donor Liver Transplant Recipient With Immunosuppressive Therapy of Cyclosporine A: A Case Report
  1784. Comparison of oral flora before and after triple therapy for Helicobacter pylori eradication in patient with gastric disease
  1785. 3D Confinement Effects ontextit {Helicobacter pylori} Swimming
  1786. sncRNAs packaged by Helicobacter pylori outer membrane vesicles attenuate IL-8 secretion in human cells
  1787. The protective effect of Helicobacter pylori infection on the susceptibility of multiple sclerosis
  1788. Eradication of Helicobacter pylori through the inhibition of urease and peptide deformylase: Computational and biological studies
  1789. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: A systematic review and meta‐analysis of observational studies
  1790. Helicobacter pylori infection is associated with diabetes among Chinese adults
  1791. Dukku and Baekam springwater inhibit the urease activity of Helicobacter pylori
  1792. Interpretation of the principles and strategies for the treatment of Helicobacter pylori infection from the perspective of integrated medicine
  1793. Inhibitory effect of medicinal plants from Cameroon on the growth and adhesion of Helicobacter pylori
  1794. Current information on the association of Helicobacter pylori with autophagy and gastric cancer
  1795. Importance of the Cys124− Cys128 intermolecular disulfide bonding for oligomeric assembly and hemolytic activity of the Helicobacter pylori TlyA hemolysin
  1796. Hydrotalcite Can Prevent the Damaging Effects of Helicobacter pylori on Gastric Epithelial Cells—CORRIGENDUM
  1797. The relationship between Helicobacter pylori infection and depressive symptoms in the general population in China: The TCLSIH cohort study
  1798. Bismuth supplements as the first‐line regimen for Helicobacter pylori eradication therapy: Systemic review and meta‐analysis
  1799. Helicobacter pylori-Induced DNA Damage Is a Potential Driver for Human Gastric Cancer AGS Cells
  1800. Antacids may increase the appearance of white opaque substance in Helicobacter pylori-eradicated gastric epithelial neoplasia
  1801. Endoscopic and Histological Findings among Israeli Populations Infected with Helicobacter pylori: Does Ethnicity Matter?
  1802. How Causal are Microbiomes? A Comparison with the Helicobacter pylori Explanation of Ulcers
  1803. Relationship between Helicobacter pylori infection and osteoporosis: a systematic review and meta-analysis
  1804. Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database
  1805. A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication
  1806. Case Histories of Significant Medical Advances: Eradicating Helicobacter pylori Infections to Treat Ulcers
  1807. Helicobacter pylori infection in rehabilitation staff younger than 35 years: Infection surveillance for three years
  1808. CagW, a VirB6 homologue interacts with Cag-type IV secretion system substrate CagA in Helicobacter pylori
  1809. Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial
  1810. … modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective …
  1811. Association between Helicobacter pylori gastritis and dental diseases: A cross‐sectional, hospital‐based study in Eastern Saudi Arabia
  1812. Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development
  1813. The risk of Helicobacter pylori infection for adverse pregnancy outcomes: A systematic review and meta‐analysis
  1814. Chronic CagA‐positive Helicobacter pylori infection with MNNG stimulation synergistically induces mesenchymal and cancer stem cell‐like properties in gastric …
  1815. Helicobacter pylori Antral Density More Valuable than Corporal Density in Chronic Gastritis Patients
  1816. FC022 Helicobacter pylori COLONISATION INCREASES PHOSPHATE BINDER PILL BURDEN IN DIALYSIS PATIENTS
  1817. Non-malignant Helicobacter pylori-Associated Diseases
  1818. Panning using a phage-displayed random peptide library to identify peptides that antagonize the Helicobacter pylori ArsS acid-sensing domain
  1819. Prevalence of Helicobacter pylori infection among dyspeptic patients with and without type 2 diabetes mellitus in Nigeria.
  1820. HISTOLOGICAL PROFILE OF Helicobacter pylori-INDUCED CHRONIC GASTRITIS: ABOUT 227 CASES
  1821. Genetic polymorphisms in TLR1, TLR2, TLR4, and TLR10 of Helicobacter pylori-associated gastritis in Thai population
  1822. Biochemical characterization of Helicobacter pylori α1–3-fucosyltransferase and its application in the synthesis of fucosylated human milk oligosaccharides
  1823. Correlation Analysis of Mental Health Status and Sleep Quality in Helicobacter pylori Positive Patients
  1824. Endoscopic Mucosal Phenotypes in the Helicobacter pylori Infection
  1825. In vitro anti-Helicobacter pylori activity of aqueous extract from Persian Oak testa
  1826. Helicobacter pylori Eradication Therapy for Functional Dyspepsia: A Meta-Analysis by Region and H. pylori Prevalence
  1827. Gastric Cancer with Submucosal Invasion after Successful Helicobacter pylori Eradication: A Propensity Score-Matched Analysis of Patients with Annual Patient …
  1828. Insights Into Pediatric Autoimmune Gastritis: Is There a Role for: Helicobacter pylori: Infection?
  1829. Association between Gastric Pathology and Hepatitis B Virus Infection in Patients with or without Helicobacter pylori
  1830. Mo1348 Helicobacter pylori INFECTION STATUS IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PATIENTS
  1831. Detection of Helicobacter pylori with clarithromycin resistance‐associated mutations using peptide nucleic acid probe‐based melting point analysis
  1832. Increased Serum Interleukin-10 Could lead to Allergic Disease Development in Helicobacter pylori Infected Adult
  1833. The Association between Helicobacter pylori Infection and Glycated Hemoglobin A in Diabetes: A Meta-Analysis
  1834. Complete Genome Sequence of Helicobacter pylori Strain GD63, Isolated from a Vietnamese Patient with a Gastric Ulcer
  1835. Immunoinformatics Approach to Design a Novel Epitope-Based Oral Vaccine Against Helicobacter pylori
  1836. Prevalence of Helicobacter pylori in Turkish children with celiac disease and its effect on clinical, histopathological, and laboratory parameters
  1837. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates
  1838. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis
  1839. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption?
  1840. Importance of Toll-like Receptors in Pro-inflammatory and Anti-inflammatory Responses by Helicobacter pylori Infection
  1841. Seroprevalence and determinants of Helicobacter pylori infection among asymptomatic under-five children at a Tertiary Hospital in the South-Western region of …
  1842. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score …
  1843. Combined effect between WT1 methylation and Helicobacter pylori infection, smoking, and alcohol consumption on the risk of gastric cancer
  1844. Clarithromycin versus levofloxacin-based regimens for Helicobacter pylori eradication in the Kurdistan Region of Iraq: A randomized clinical trial
  1845. The most influential articles in Helicobacter pylori research: A bibliometric analysis
  1846. Helicobacter pylori‐induced YAP1 nuclear translocation promotes gastric carcinogenesis by enhancing IL‐1β expression
  1847. … modified carboxymethyl chitosan-graft-stearic acid polymeric nano-micelles as a targeted delivering carrier of clarithromycin for Helicobacter pylori: Preparation and in …
  1848. Shifts in the human gut microbiota structure caused by quadruple Helicobacter pylori eradication therapy
  1849. Clarithromycin-Susceptible But Virulent Helicobacter pylori Strains Infecting Iranian Patients’ Stomachs
  1850. Association between infection with Helicobacter pylori and platelet indices among school-aged children in central Ethiopia: a cross-sectional study
  1851. Linked color imaging identifies important risk factors associated with gastric cancer after successful eradication of Helicobacter pylori
  1852. Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis
  1853. Prevalence of and Helicobacter pylori infection rate in heterotopic gastric mucosa on histological analysis of duodenal specimens from patients with duodenal …
  1854. Characterization of gastric cells infection by diverse Helicobacter pylori strains through Fourier-transform infrared spectroscopy
  1855. VacA Genotype in Helicobacter pylori
  1856. Prevalence of Helicobacter pylori Infection among Internally Displaced Persons from Bakassi Peninsular and Etim Ekpo in South Southern, Nigeria
  1857. Diagnostic Techniques and Antimicrobial Susceptibility Test of Helicobacter pylori Infection in Gashua Town.
  1858. The role of high sensitive C-reactive protein and histopathological evaluation in chronic gastritis patients with or without Helicobacter pylori infection
  1859. … nanospheres as signal tags and target-triggered strand displacement reaction as signal amplification for highly sensitive detection of Helicobacter pylori DNA
  1860. Gastric Xanthoma Is a Predictive Marker for Early Gastric Cancer Detected after Helicobacter pylori Eradication
  1861. Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric …
  1862. Ranitidine, A Potential Option for Helicobacter pylori Eradication
  1863. Half‐dose clarithromycin‐containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single‐center, open‐label …
  1864. Helicobacter pylori INFECTION IS AN AVOIDABLE RISK FACTOR FOR PARKINSON’S DISEASE.
  1865. … microRNA Gene Methylater in the Precancerous Background Mucosa with and without Gastric Cancer: Analysis of Effects of Helicobacter pylori Eradication and Long …
  1866. Once‐daily rabeprazole, levofloxacin, clarithromycin‐MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)
  1867. Relationship between Helicobacter pylori cytotoxin-associated gene A protein with clinical outcomes in patients with rheumatoid arthritis
  1868. Roles of Adhesion to Epithelial Cells in Gastric Colonization by Helicobacter pylori
  1869. … the Bifunctional 2‐C‐Methyl‐d‐erythritol 4‐Phosphate Cytidylyl Transferase/2‐C‐Methyl‐d‐erythritol‐2, 4‐cyclopyrophosphate Synthase (IspDF) of Helicobacter pylori
  1870. Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line Helicobacter pylori therapy in clinical practice: A pilot study
  1871. Twice daily short‐message‐based re‐education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study
  1872. The Story of Helicobacter pylori: Depicting Human Migrations from the Phylogeography
  1873. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis
  1874. Development of an animal model of Helicobacter pylori (Indian strain) infection
  1875. The impact of Helicobacter pylori on the presence of Barrett’s esophagus in Azerbaijan, a high-prevalence area of infection
  1876. Does anti-Helicobacter pylori immunohistochemical staining has a confirmative role in the definitive diagnosis of negative gastric biopsy samples stained with …
  1877. Preliminary X-ray crystallographic studies on the Helicobacter pylori ABC transporter glutamine-binding protein GlnH
  1878. Interleukin-6 Expression in Serum, Gastric Juice and Gastric Mucosa of Helicobacter pylori Positive Gastric Cancer Patients
  1879. Correlations between gastric Helicobacter pylori infection and colorectal polyps or cancer
  1880. Detection of the clarithromycin resistance of Helicobacter pylori in gastric mucosa by the amplification refractory mutation system combined with quantitative real‐time …
  1881. Novel metabolites from Trichoderma atroviride against human prostate cancer cells and their inhibitory effect on Helicobacter pylori and Shigella toxin producing …
  1882. Decreased circulating interleukin-33 concentration in Helicobacter pylori-infected patients with peptic ulcer: Evaluation of its association with a cytokine gene …
  1883. The Effect of Red Rose Extract on Helicobacter pylori Eradication: A Randomized Controlled Clinical Trial
  1884. Protein changes in gastric epithelial cells RGM‐1 in response to Helicobacter pylori infection
  1885. Diagnosis of Helicobacter pylori in cholelithiasis and cholecystitis: by histology and serological association
  1886. Minor allele of rs1057317 polymorphism in TLR4 is associated with increased risk of Helicobacter pylori ‐induced gastric cancer
  1887. Effect of Helicobacter pylori Treatment on Long-Term Mortality in Patients with Hypertension
  1888. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori
  1889. Association between Helicobacter pylori Infection and Iron Deficiency Anemia in School-aged Iranian Children
  1890. Initial Reverse Transcription is Essential for Reliable Helicobacter pylori 23S rDNA Real-Time PCR Diagnostics from Fecal Samples.
  1891. Phenotypic and genotypic characterization of Helicobacter pylori isolated from Egyptian endoscopic units
  1892. Tailored therapy in treatment of Helicobacter pylori infectionbasedon clarithromycinsensitivity
  1893. Application of PCR and Microscopy to Detect Helicobacter pylori in Gastric Biopsy Specimen among Acid Peptic Disorders at Tertiary Care Centre in Eastern Nepal
  1894. Prevalence of Helicobacter pylori Infection in Patients with Dyspeptic Symptoms in Damaturu Metropolitan
  1895. Optimization of HPMC K100M and Sodium Alginate Ratio in Metronidazole Floating Tablets for the Effective Eradication of Helicobacter pylori
  1896. Evaluating the Accuracy of the Endoscopic ABC Classification System in Diagnosing Helicobacter pylori-Infected Gastritis
  1897. The prognostic role of Helicobacter pylori in gastric cancer patients: a meta-analysis
  1898. Erratum to “Epidemiological and Clinical-Pathological Aspects of Helicobacter pylori Infection in Brazilian Children and Adults”
  1899. Frequency of Helicobacter pylori in patients with functional dyspepsia.
  1900. Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile
  1901. High Efficacy of Rapid Urine Test for Diagnosis of Helicobacter pylori Infection in Thai People
  1902. Evaluation of the Relationship Between Childhood Asthma and Helicobacter pylori Sero-Prevalence
  1903. Correlation Analysis of Pathways and Operons of Helicobacter pylori Resistance Genes Using Bibliometrics.
  1904. Detection of Helicobacter pylori and its virulence genes (cag A, dup A, and vac A) among patients with gastroduodenal diseases in Chris Hani Baragwanath …
  1905. Helicobacter pylori Induces GATA3-Dependent Chitinase 3 Like 1 (CHI3L1) Upregulation and Contributes to Vascular Endothelial Injuries
  1906. The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer
  1907. Testing of Helicobacter pylori by Endoscopic Biopsy: The Clinical Dilemma of Suppressive Conditions
  1908. Selected commensal bacteria change profiles of Helicobacter pylori‐induced T cells via dendritic cell modulation
  1909. The Gastro-protective Effect of Ginger (Zingiber officinale Roscoe) in Helicobacter pylori Positive Functional Dyspepsia
  1910. Relationship between type II diabetes mellitus and Helicobacter pylori infection in Erbil city
  1911. Dynamics of Helicobacter pylori infection in infants during the first six months of life
  1912. Cost‐effectiveness analysis and effectiveness of pharmacist‐managed outpatient clinics in Helicobacter pylori eradication therapy
  1913. Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection
  1914. Sequestration inside the yeast vacuole may enhance Helicobacter pylori survival against stressful condition
  1915. Identification and characterisation of Helicobacter pylori O‐acetylserine‐dependent cystathionine β‐synthase, a distinct member of the PLP‐II family
  1916. Optimization of 13C‐urea breath test threshold levels for the detection of Helicobacter pylori infection in a national referral laboratory
  1917. Association between a regular arrangement of collecting venules and absence of Helicobacter pylori infection in a European population
  1918. Helicobacter pylori DNA promotes cellular proliferation, migration, and invasion of gastric cancer by activating toll-like receptor 9
  1919. Effects of Pathogenesis Outcomes on Adherence Rate and Gene Toxicity in Helicobacter pylori